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I shall pass this way but once;   
Any good that I can do or any kindness I can show to any human being;   
Let me do it now.  
Let me not defer nor neglect it,  
For I shall not pass this way again. 
 
Étienne de Grellet du Mabillier (1773−1855) 
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Objective: Our objective was to assess unconjugated bilirubin (UCB) as a biomarker 
candidate for schizophrenia and schizoaffective spectrums disorder and its clinical 
severity. For that purpose we prepared two different studies: a five year transversal 
restrospective study, and a one year longitudinal prospective study. 
Methods: For our five years transversal restrospetive study we searched for an eventual 
correlation between UCB mean levels, duration of psychiatric admission, and diagnosis 
in 255 individuals, including 56 healthy controls and 199 acute patients (namely 44 with 
schizophrenia, 99 with schizoaffective disorder and 56 with bipolar disorder). For our 
one year longitudinal prospective study 88 psychotic patients completed a first 
assessment during relapse at ward admission, half with schizophrenia half with 
schizoaffective disorder. Forty−four acute bipolar patients were used as controls. In a 
twelve−month follow−up we collected longitudinal protocol (laboratory, 
psychopathological and psychosocial data) from 60 of those patients, half with 
schizophrenia half with schizoaffective disorder. 
Results: In our five year transversal retrospective study we found a statistically 
significant difference between UCB mean levels of patients with schizophrenia (0.41 
mg/dL) versus patients with schizoaffective (0.34 mg/dL) (p<0.03), bipolar disorders 
(0.28mg/dL) (p<0.001) and healthy controls (0.28)(p<0.001) using Bonferroni multiple 
comparison test. We also found a statistically significant difference (p<0.04) between 
UCB mean levels of patients with schizoaffective disorder (0.34 mg/dL) and bipolar 
disorder (0.28 mg/dL). Regarding average admissions duration for the five−year period, 
diagnosis and UCB level, when applying a linear regression ANOVA model, with 
average admissions duration as a dependent variable we  found statistically significant 
difference between schizophrenia (29 days) versus bipolar (16 days) (p<0.001) but not 
with patients with schizoaffective disorder. In our one year longitudinal prospective 
study during acute psychotic episode (N=88) we found: a statistically significant 
difference (ANOVA;  p=0.002), confirmed after post−hoc Bonferroni multiple 
comparisons between between UCB mean levels of schizophrenia (N=44) and both 
schizoaffective (N=44) (p=0.05) and bipolar controls (N=44) (p=0.05);  a positive 
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Pearson’s correlation (r=0.314) between UCB mean levels and Personal and Social 
Performance item d) “disturbing and aggressive behavior”;  and a positive correlation 
(R2=0.223), with statistically significance (p=0.008), between UCB mean levels and 
mean length of stay at the psychiatric ward in schizoaffective patients who completed 
full protocol (N=30). During partial remission (N=60) we found: a statistically ANOVA 
significant difference (p=0.006), confirmed after post−hoc Bonferroni multiple 
comparisons between between UCB mean levels of schizophrenia (N=30) and 
schizoaffective (N=30) (p=0.05); plus a negative Pearson’s correlation (r=−0.399) 
between UCB mean levels and Positive And Negative Syndrome Scale item G7 
“psychomotor retardation”. Comparing first and second assessments, with paired 
samples T−test, we found a statistically significant difference (p=0.034) in UCB mean 
levels only among patients with schizoaffective disorder (N=30).  
Conclusion: there is an interesting potential in the research of UCB as a biological 
marker for schizophrenia and schizoaffective spectrums disorders, for both relapse and 
remission episodes of these syndromes. 
 
Keywords: unconjugated bilirubin, schizophrenia, schizoaffective, psychosis. 
  




Objectivo: O nosso objectivo consistiu em avaliar a bilirrubina não conjugada (UCB) 
como candidato a biomarcador no espectro e na gravidade da esquizofrenia e 
perturbação esquizoafectiva. Para esse fim preparámos dois estudos: um estudo 
transversal restrospetivo de cinco anos, e um estudo longitudinal prospectivo com um 
ano de duração. 
Métodos: No nosso estudo transversal retrospetivo de 5 anos procurámos correlação 
entre os níveis médios de UCB, duração média de internamento e o diagnóstico em 255 
indivíduos, incluindo 56 controlos saudáveis e 199 doentes (nomeadamente 44 com 
esquizofrenia, 99 com perturbação esquizoafectiva e 56 com perturbação bipolar). No 
nosso estudo longitudinal prospetivo 88 doentes psicóticos completaram a primeira 
avaliação durante internamento psiquiátrico em contexto de episódio psicótico agudo, 
metade com esquizofrenia, metade com perturbação esquizoafectiva. Nesta fase 44 
doentes com perturbação bipolar, foram usados como controlos. Aos doze meses de 
seguimento completámos o protocolo longitudinal (dados laboratoriais, 
psicopatológicos e psicossociais) de 60 doentes, metade com esquizofrenia, metade com 
perturbação esquizoafectiva. 
Resultados: No nosso estudo transversal retrospetivo de 5 anos encontrámos diferença 
estatisticamente significativa, após teste de multicomparações de Bonferroni, entre os 
níveis médios de UCB dos doentes com esquizofrenia (0.41 mg/dL) e os doentes com 
perturbação esquizoafectiva (0.34 mg/dL) (p<0.03), os doentes com perturbação bipolar 
(0.28mg/dL) (p<0.001) e também os controlos saudáveis (0.28) (p<0.001). Encontrámos 
ainda diferença estatisticamente significativa entre os níveis médios de UCB de doentes 
com perturbação esquizoafectiva (0.34 mg/dL) e perturbação bipolar (0.28 mg/dL) 
(p<0.04). Relativamente à duração média de internamentos durante o período dos 5 
anos, ao diagnóstico e ao nível de UCB, quando aplicámos um modelo de regressão 
linear ANOVA, com a duração média dos internamentos como variável dependente, 
encontrámos uma diferença estatisticamente significativa (p<0.001)  entre os doentes 
com esquizofrenia (29 dias) e os doentes  com perturbação bipolar (16 dias) mas não 
com os doentes com perturbação esquizoafectiva. No nosso estudo longitudinal 
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prospetivo de 1 ano, encontrámos, aquando da primeira avaliação durante o episódio 
psicótico agudo (N=88): uma diferença estatisticamente significativa (ANOVA;  
p=0.002), confirmada após teste de multicomparações de Bonferroni, entre doentes com 
esquizofrenia (N=44), quer com os doentes com perturbação esquizoafectiva (N=44) 
(p=0.05), quer com os controlos com perturbação bipolar (N=44) (p=0.05). 
Encontrámos também uma correlação positiva (Pearson’s r=0.314) entre os valores 
médios de UCB e o item d) “disturbing and aggressive behavior” da escala de 
Personal and Social Performance; e ainda uma correlação positiva (R2=0.223), com 
significância estatística (p=0.008), entre os níveis médios de UCB e a duração média de 
internamento psiquiátrico dos doentes com perturbação esquizoafectiva que 
completaram o protocolo (N=30). Durante a remissão parcial, aquando da segunda 
avaliação (N=60), encontrámos: uma diferença estatisticamente significativa (ANOVA; 
p=0.006), confirmada após teste de multicomparações de Bonferroni (p=0.05) entre os 
doentes com esquizofrenia (N=30) e perturbação esquizoafectiva (N=30); bem como 
uma correlação negativa (Pearson’s r=−0.399) entre os níveis médios de UCB e o item 
G7 “psychomotor retardation” da Positive And Negative Syndrome Scale. Ao 
compararmos a primeira com a segunda avaliação (teste T Student para amostras 
emparelhadas) encontrámos uma diferença estatisticamente significativa (p=0.034) nos 
valores médios apenas entre doentes com perturbação esquizoafectiva (N=30).  
Conclusão: existe um interessante potencial na investigação da UCB como biomarcador 
das psicoses e respectiva gravidade, quer no espectro da esquizofrenia, quer no da 
perturbação esquizoafectiva, seja na recaída ou na remissão. 
 
Palavras−Chave: bilirrubina não conjugada, esquizofrenia, esquizoafectiva, psicose. 






For the theoretical background of our thesis we included one epistemological 
perspective about the schizophrenia disorders spectrum plus a review regarding the 
correlation between UCB and schizophrenia. 
Then we present a chapter that tries to summarize the epistemological and historical 
background for a broader schizophrenia spectrum, going from schizophrenia to bipolar 
disorder, with schizoaffective disorder right in between. We believe that without this 
schizophrenia – schizoaffective – bipolar spectra concept in our minds all our efforts 
will keep failing one of the hardest quests: the never−ending search for biomarkers in 
schizophrenia and related disorders. 
Afterwards we included an already published review, supervised by us, becoming the 
master thesis of one of our students, and fully focused on the most important research 
findings contributing to the hypothesis of UCB as a biomarker for schizophrenia 
disorders. Many previous attempts have been made on the search for biomarkers in 
schizophrenia, but without significant success to our date. Mostly because of various 
kind of problems that have emerged in the last decades regarding the nosology and 
etiopathogeny of the psychotic disorders of the schizophrenia spectrum. In the last 
twenty years some studies have been published suggesting UCB as possible biomarker 
for schizophrenia spectrum disorders. On one hand it seems that UCB may have some 
utility for the categorical distinction with bipolar disorder, while on the other hand it 
seems that UCB may also become a valuable dimensional indicator for acute 
schizophrenic psychotic episodes. 
The methods section consisted on the adaptation of one perspective article published for 
the dissemination of our study protocol.  
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The results section will be a compilation of two different manuscripts: one already 
published article with five years of retrospective data and another, yet unpublished, fully 
original paper with twelve months of prospective data. All of them exploring 
correlations between UCB mean levels and schizophrenia variables in human subjects.       
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Schizophrenia − schizoaffective − bipolar spectra: an epistemological perspective 
Many authors have written regarding and discussing about the conceptual history of 
schizophrenia (Garrabé 1992, Berrios et al 2003). One could assume that, before 
modern age, schizophrenia patients would be included under the unspecific terms as 
melancholia or mania, terms already in use in classic age, depending if the predominant 
psychomotor symptoms were retardation or agitation (Zilborg 1941). But in modern age 
this epopee started with the first description of démence, a deteriorating psychological 
condition (Pinel 1801), and démence précoce, nothing more than a progressive, 
heritable decline in function in young people (Morel 1852). Later the concept of 
dementia praecox was adapted (Pick 1891) and developed as an ingeniously and 
consistent nosological entity, described as a chronic, deteriorating psychotic disorder 
characterized by rapid cognitive disintegration, usually beginning in the late teens or 
early adulthood (Kraepelin 1896). Although these words could be considered French 
and Latin translations of the same term, they were not quite true synonymous as 
concepts. There was, indeed, an abyss separating démence précoce from dementia 
praecox (Minkowski 1925). Nevertheless dementia praecox was the starting point for 
what would be the first ever use of the term, and concept for schizophrenia, describing a 
group of diseases that cause changes in thought processes and behavior in humans as 
well as difficulties relating to the world (Bleuler 1911). 
Throughout our readings we collected some more outstanding citations that clearly 
show how the scientific community has raised, in the last half century, so many 
different opinions regarding this fascinating topic. Thus, schizophrenia has been labeled 
by various authors in many diverse manners such as: the graveyard of neuropathologists 
(Plum 1972), nothing more than a myth with a strong genetic component (Kety 1974); 
existing since the birth of humanity (Strömgren 1982), a scientific delusion (Boyle 
1990), representing nothing than a different way of being human (Jenner et al 1993) or 
the price mankind pays nature for language use (Crow 1997). 
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The schizophrenia – schizoaffective – bipolar meta–spectrum. 
For decades that clinicians and researchers have been thinking and writing about the 
spectrum of schizophrenia disorders. Indeed both Kraepelin and Bleuler believed in 
schizophrenia as a spectrum, both in a clinical (individual) and hereditary (family) 
continuum, from just some exquisite personality traits to unquestionable chronic and 
debilitating psychosis (Weller 1987). Other authors would put the schizophrenia 
spectrum disorders on different levels of continuum: developmental, psychofunctional, 
existential and genetic (Reich 1975). 
An intermediate entity between schizophrenia and bipolar affective disorder is often the 
so called schizoaffective disorder. Patients with these schizoaffective psychoses are less 
likely to achieve a full remission than patients with bipolar disorders, who also present a 
much smaller prevalence of residual state between episodes (Angst et al 1980). 
Considerable debate have surrounded the inclusion of schizoaffective disorder in 
psychiatric nosology: some authors believe that schizoaffective disorder may be a 
variant of schizophrenia in which mood symptoms are unusually prominent but not 
unusual in type; while others believe it is a condition that may instead reflect a severe 
form of bipolar disorder in which episode−related psychotic symptoms fail to remit 
completely between mood episodes. Alternatively, schizoaffective disorder could 
correspond to the co−occurrence of two relatively common psychiatric illnesses: 
schizophrenia and bipolar disorder, or even represent a third and different type of 
psychosis, completely autonomous from the bipolar and schizophrenia categories 
(Abram 2008). On the other hand schizoaffective disorder could be an interform created 
by a combination of some, but not all, of the unknown aetiological factors responsible 
for schizophrenia and some, but not all, of the equally unknown factors responsible for 
bipolar disorder; or last but not least, some combination of the above described five 
theories (Kendell 1986). Schizoaffective disorder diagnosis is, indeed, an authentic 
conundrum in the clinical setting (Wilson et al 2014).  
Some authors suggest a genetic susceptibility continuum spanning across schizophrenia 
and bipolar disorder and including, at its two extreme ends, unique genetic factors 
associated with each disorder and a middle zone of overlap, occupied by schizoaffective 
disorder and containing shared genetic factors (Owen et al 2007). Several twin analysis 
are consistent with genetic influences on schizoaffective episodes being entirely shared 
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with genetic influences on schizophrenic and manic episodes, while association studies 
suggest the possibility of some relatively specific genetic influences on broadly defined 
schizoaffective disorder (Cardno and Owen 2014). 
More recently influent researchers wrote about the slow death of the concept of 
schizophrenia and the painful birth of the psychosis spectrum (Guloksuz and van Os 
2018). Soon there were many voices rebutting this idea: some claimed that the concept 
of schizophrenia is still alive (Kahn 2018); some argued that, although clearly not well 
and with limited validity, the concept of schizophrenia has a continued utility (Zoghbi 
and Lieberman 2018); and others almost shouted that the half−alive concept of 
schizophrenia is still better than the spectrum of everything (Bora 2018). 
After reading this insightful discussion we had to agree that schizophrenia is part of a 
spectrum, but it does not represent the extreme of a normally distributed trait (Curtis 
2017), and shall be kept as a useful concept (Lawrie 2016) both for researchers, 
clinicians, patients, families and society. Indeed, we do not believe in a psychotic 
spectrum of everything but instead in a meta−spectrum composed by three different 
spectra: bipolar disorders spectrum, the schizophrenias spectrum, and the 
schizoaffective disorders spectrum. Each of those spectra would include different 
nosological independent entities, from personality disorder to chronic full−blown 
psychosis. 
 
The bipolar disorders spectrum 
To understand the complexity of the concepts include in bipolar disorders spectrum we 
point some relevant aspects about the classification and description of these. 
 Classic bipolar disorder (Kleist 1911), previously known as manic depressive 
insanity, nowadays known as bipolar I (Akiskal and Pinto 1999), with manic or 
mixed episode, with or without major depressive episodes, not forgetting the 
renewed interest in the new mixed features specifier for episodes of mood disorders 
(Stahl et al, 2017;  Vázquez et al, 2018). 
 Other bipolar disorders in all its other modern subtypes (Akiskal and Pinto 1999): I 
½ protracted hypomania without depression; II depressive and hypomanic episodes; 
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II ½ depressive episodes with cyclothymic temperament; III depressive episodes 
with antidepressant−induced hypomania; III ½ bipolar disorder with substance 
abuse; IV depressive episodes with hyperthymic temperament; V depression with 
mixed hypomania; VI bipolarity in the setting of dementia. 
 Hyperthymic and cyclothymic temperaments (Akiskal and Malya 1987). 
 
The schizophrenias spectrum 
Also, for the clarification of concepts in schizophrenia spectrum, we highlight that: 
 Schizoid and schizothypal personality disorders (Bolinskey et al 2017) and all its 
equivalents are cited in all previous versions of the World Health Organization’s 
(WHO) International Classification of Diseases (ICD), such as latent schizophrenia, 
borderline schizophrenia, prodromal schizophrenia, prepsychotic schizophrenia, 
pseudoneurotic schizophrenia and pseudopsychopathic schizophrenia are at the 
milder extreme of this spectrum. 
 Paranoid personality disorder, delusional disorder (previously known as paranoia) 
and paraphrenia (Ravindran et al 1999) are included in the spectrum. 
 Schizophrenia in all old subtypes: simple, hebephrenic or disorganized, paranoid, 
residual, undifferentiated, catatonic (McGlashan and Fenton 1991), and even other 
obscure clinical scenarios, more common in European eastern countries such as 
cenesthopathic schizophrenia (Basov 1980) or sluggish schizophrenia (Jargin 2011) 
would constitute the more extreme severe conditions at the other end of our 
spectrum  proposal. 
 
The schizoaffective disorders spectrum 
Our contribution for this meta−spectrum would be the proposal of a new spectrum for 
schizoaffective disorders that would include: 
 Schizoaffective patients included in the original description (Kasanin 1933) plus the 
newer descriptions such as schizomania (Carloni and Spadoni 1959, van Os et al 
1995) and schizobipolar (Stahl 2013). 
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 Cycloid psychosis on its classic forms: hyperkinetic−akinetic motility psychosis; 
excited−inhibited confusion psychosis; and anxiety−happiness psychosis (Leonhard 
1979, Zaudig 1990, Pfuhlmann 2004, Jabs 2007, van der Kerkhof et al 2016).  
 Borderline personality disorder patients, who may have brief psychotic episodes 
(but not enough for schizophrenia diagnosis) independently of important mood 
changes (but also not enough for bipolar disorder diagnosis) (Zimmerman 2013, 
Slotema et al 2018). We assume this idea as the most controversial of our proposal 
as psychotic symptoms in borderline personality disorder continue to be poorly 
understood and further research should try to ascertain the relationships between 
hallucinations and delusions on one hand and the processing of trauma, emotion 
regulation, distress tolerance and interpersonal sensitivity on the other (D’ Agostino 
et al 2019). 
With this short epistemological perspective we want to raise awareness, among 
clinicians but also among researchers, regarding the importance of the spectrum concept 
for the understanding and studying of idiopathic psychoses (previously known as 
nonorganic psychoses), especially regarding the authentic conundrum of schizoaffective 
disorder. 
In the American Psychiatry Association’s (APA) Diagnostic and Statistical Manual of 
Mental Disorders, fifth edition (DSM 5), the diagnosis of schizoaffective disorder can 
be made only if full mood disorder episodes have been present for the majority of the 
total active and residual course of illness, from the onset of psychotic symptoms up until 
the current diagnosis. In earlier DSM versions, the boundary between schizophrenia and 
schizoaffective disorder was only qualitatively defined, leading to poor reliability. This 
change will provide a clearer separation between schizophrenia with mood symptoms 
from schizoaffective disorder and will most likely reduce rates of diagnosis of 
schizoaffective disorder while increasing the stability of this diagnosis once made 
(Malaspina et al, 2013).  
On the other hand, clinicians all around the world have shown small improvements in 
accurately diagnosing vignettes, using the World Health Organization’s International 
Classification of Diseases, 11th edition (ICD 11). It seems that the discrepancy in 
diagnose schizoaffective disorder is related primarily to the presence of mood 
symptoms and discrepancies about whether those symptoms are more consistent with 
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schizoaffective disorder or a mood disorder diagnosis. Continuing to identify ways to 
more accurately capture this clinical picture will be important in the future as well as 
systematic efforts to educate clinicians about differential diagnosis (Peterson et al, 
2019) 
As a small contribute for this theoretical reflection we would like to present here an 
historical chronology for the schizophrenia–schizoaffective–bipolar spectra (Table 1) 
plus a tridimensional model for these spectra (Figure 1): the first axis for categories 
(affective versus nonaffective psychoses), the second axis for dimensions (personality 
versus full blown psychosis), and a third axis for biomarkers (remission versus relapse). 
We believe that without the schizophrenia–schizoaffective–bipolar spectra concept in 
our minds all our efforts will keep failing one the hardest quest: searching for 
biomarkers in schizophrenia and related disorders. 
Generally, a biomarker can be developed for three main purposes: diagnostic (to 
classify as having a disease); prognostic (to make predictions on who will develop a 
disease); or theranostics (to predict an individual’s disease response to a particular 
treatment) (Weickert et al 2013). Unfortunately, there are still no validated and reliable 
biomarkers for schizophrenia in clinical use (Weickert et al 2013, Perkovic et al 2017). 
The fact that schizophrenia is on heterogenic disorder with multiple probable causes 
with distinct biological mechanisms means that attempting to find a single biomarker or 
group of biomarkers that would coincide with all cases of schizophrenia is unlikely 
(Weickert et al 2013). We  do  not  have, indeed,  strong biological  markers  that  could  
help  disentangle  this  heterogeneity  and  be  useful  in clinical  practice  (Dazzan  
2014). 
In an attempt to change this, efforts have been made to find biomarkers for 
schizophrenia (Hallak et al 2015). Though many potential biomarkers have been 
studied, some of the most promising and potentially clinically relevant include 
neuroimaging biomarkers (Goldsmith et al 2018). Since neuroimaging techniques 
results are inconclusive, a search, in recent years, for blood−based biomarkers for 
schizophrenia has been conducted (Lai et al 2016). The most frequently used 
blood−based biomarkers candidates in schizophrenia have been divided into six 
categories: brain−derived neurotrophic factor; immune function; epigenetics / genetics; 
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transcriptome / proteome studies; neurochemistry; and oxidative stress response (Lai et 
al 2016).  
As any biomarker in medicine a biomarker for schizophrenia has to have clinical utility 
and this will take time, money, and coordinated research to develop (Weickert et al 
2013). We emphasize other research groups’ efforts in the study of UCB as a biomarker 
in schizophrenia, all around the world, in prestigious institutions such as the Milan 
Center for Neuroscience (Bentivegna et al 2019) or the Yale School of Medicine 
(Pradeep et al 2019). There is indeed an impending necessity for further research in this 
area and we are aware of those efforts (Gama Marques 2020). 
 
Table 1: Epistemology of the schizophrenia − schizoaffective − bipolar spectra. 
Author Date Better Prognosis Spectra Worse Prognosis Spectra 
Pinel  1801 Mania Melancholia 
Démence 
Falret  1853 
Folie Circulaire 







Bleuler 1911  
Schizophrenias 
Kasanin 1933 Schizoaffective Disorder 
Leonhard 1957 Cycloid Psychosis  
ICD 9 1979  Schizoaffective 




ICD 10 1994 
DSM 5 2013 
ICD11 2018 
ICD: International Classification of Diseases;  DSM: Diagnostic and Statistical Manual of Mental Disorders 
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Figure 1: The Schizophrenia − Schizoaffective − Bipolar spectra. 
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Unconjugated bilirubin and schizophrenia: a review. 
Schizophrenia (SZ) is an incredibly complex syndrome, a group of signs and symptoms 
of unknown etiology mainly defined by observed signs of psychosis;  in its most 
common form, it presents itself with paranoid delusions and auditory hallucinations late 
in adolescence or in early adulthood (Insel 2010) . Currently available pharmacological 
treatments have limited efficacy, and there we have seen little substantial improvement 
since the advent of the first antipsychotics in the 1950s (Hallak et al 2015).  
Unconjugated bilirubin is the water−insoluble fraction of total bilirubin in the serum. 
After it is bound to albumin and transported to the liver, it processed by the hepatic 1A1 
isoform of uridinediphosphate−glucuronosyltransferase (UGT1A1) and becomes 
conjugated bilirubin (direct bilirubin), which can in turn be excreted into the bile 
(Hirschfields et al 2006). In practice, unconjugated bilirubin is calculated through the 
difference between the directly measurable levels of serum total bilirubin (TB) and 
conjugated bilirubin (CB); for this reason, unconjugated bilirubin (UCB) is also 
sometimes called indirect bilirubin. Some studies have found a possible correlation 
between UCB levels and an increased incidence of schizophrenia (Miyaoka et al 2000, 
Miyaoka et al 2008, Semnani e al 2010, Radhakrishnan et al 2011,). UCB levels may 
have both direct and indirect toxic effects for the Central Nervous System (CNS) (Brites 
et al 2012), with animal models (Gunn rat) presenting schizophrenia−like behavior 
(Hayashida et al 2009). Therefore, the measurement of serum concentration of UCB has 
been proposed as a possible biomarker for the management of schizophrenia 
(Gama−Marques et al 2017). 
 While UCB concentrations below 100 nM are able to protect the CNS against oxidative 
damage (Doré et al 1999), moderate and high levels preferentially cause early necrosis 
(Hankø et 2008). Neurons are more susceptible to UCB−induced damage than 
astrocytes (Brito et al 2008) as neurons commonly show higher levels of Reactive 
Oxygen Species (ROS), protein oxidation, and lipid peroxidation upon UCB exposure 
than astrocytes (Conforti et al 2007). Interaction of UCB causes increased polarity and 
fluidity (Rodrigues et al 2002), disrupting the neuronal membrane structure. This is 
accompanied by reduced activity of Mg2+ −ATPase aminophospholipid translocase 
(flippase) and Na + , K + −ATPase, together with enhanced intracellular levels of Ca2+, 
effects which can lead to cell destruction (Khan et al 2011). Developing neurons are 
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particularly susceptible to UCB interaction, with neurogenesis impairment, neuritic 
atrophy, and cell death by both necrosis and apoptosis (Brito et al 2002, Falcão et al 
2007). The contact results in sudden and lasting decrease in neuronal arborization 
(Fernandes et al 2009), and cells stays vulnerable to a secondary toxic stimulus (Falcão 
et al 2007). UCB also causes synaptotoxicity which has been related with potentiation 
of inhibitory synaptic transmission (Shi et al 2006) and with impairment of the 
induction of long term potentiation (Chang et al 2009). N−methyl−d−aspartate 
(NMDA) receptor mediated excitotoxic mechanism is another pathway leading to 
UCB−induced neuronal injury (Bellefontaine et al 2011). UCB was demonstrated to 
raise the extracellular concentration of glutamate, by enhancing its release mainly from 
immature neurons and overstimulating NMDA receptors (Falcão et al 2006). UCB also 
causes mitochondrial swelling (Solá et al 2002), Bax translocation and activation of 
caspase−3 (Rodrigues et al 2002). The survival and proper functioning of neurons is 
ensured by the large number of glial cells (Streit et al 2002), which include 
oligodendrocytes (OLGs), astrocytes and microglial cells. Therefore, induced glial 
damage must be considered an important event in Central Nervous System (CNS) injury 
by UCB. Astrocytes are the most abundant type of glia (Nair et al 2008) and have 
multiple homeostatic properties (Orellana et al 2008). UCB causes a rapid increase in 
the extracellular glutamate content (Fernandes et al 2004), mainly in immature 
astrocytes (Falcão et al 2005) that appears to result from the inhibition of its uptake by 
UCB (Silva et al 2001) and also from enhanced reactive astrocyte secretion (Falcão et al 
2006); excessive exposure to glutamate causes neuronal injury, and this excitotoxicity 
can be harmful to neurons and OLGs (Brites 2012). Elevated concentrations of UCB 
can cause the secretion of Tumor Necrosis Factor Alfa (TNF−α) and Interleukin 1 Beta 
(IL−1β) by astrocytes (Fernandes et al 2004);  it can also cause inhibition of cell 
endocytosis (Silva et al 2001) and upregulation of both TNF−α receptor (TNFR) 1 and 
IL−1β receptor (IL−1R)1 (Fernandes et al 2011). UCB also has deleterious effects on 
OLGs. Moderate perinatal systemic inflammation is related to deficient OLGs 
precursors’ maturation, with diminished density of myelinating, therefore causing 
long−lasting effects (Favrais et al 2012). Under these conditions, vulnerable microglia 
may modify their functional capabilities and become more susceptible to injury or aging 
(Harry et al 2012). UCB also compromises the mechanism of myelinogenesis (Brites 
2012). The microglia, which accounts for around 12% of total glial population (Ladeby 
et al 2005), were shown to be involved in neurogenesis, postlesional tissue repair and 
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synaptic stripping (Graeber et al 2011). They play a major role in synaptic pruning 
during postnatal development (Paolicelli et al 2011). The first reaction of microglia 
against UCB insult is an increase in phagocytosis (Brites 2012). Microglial cells can be 
activated or overactivated, depending on the stimuli, consequently becoming neurotoxic 
(Carson et al 2007); the cause of increased microglial activation is still unclear, but 
oxidative stress appears to have a central role (Floyd et al 2002). The most marked 
effect of UCB on microglia was shown to be elevated levels of IL−1β, which was 
related to loss of neuronal integrity (Depino et al 2005);  these cells also release the 
cytotoxic molecule glutamate when exposed to UCB (Gordo et al 2006). Additionally, 
microglia contributes to the generation of NO, an important component in 
microglia−induced neuronal death (Graber et al 2012). Finally, these cells undergo 
cytoplasmic fragmentation and nuclear condensation when exposed to UCB for longer 
periods (Silva et al 2010), thus thwarting any beneficial effect they might have in the 
protection against neuronal damage. Neuroinflammation plays a role in UCB−induced 
neuronal damage as well. UCB inhibits the function of polymorphonuclear leukocytes 
and lymphocytes (Brites 2012) and stimulates the release of proinflammatory cytokines, 
reactive oxygen species (ROS) ROS and nitric oxide (NO), which can disrupt nerve 
terminals and impair synaptic activity (Haustein et al 2010). Neurons previously 
exposed to UCB have demonstrated an increased vulnerability to a subsequent 
inflammatory injury with lipopolysaccharide or TNF−α (Falcão et al 2007), implying 
that the priming of neurons by UCB may cause long−term neurological dysfunction. A 
recent study showed that UCB can induce pyroptosis, a highly inflammatory form of 
cell death, in cultured rat cortical astrocytes (Feng et al 2018). It reported that UCB 
caused in vitro activation of caspase−1, known as an important mediator of pyroptosis 
(Bergsbaken et al 2010), which was in turn involved in plasma membrane rupture and 
loss of cell viability. 
In this paper, we review the relation between UCB and schizophrenia. We used the 
Preferred Reporting Items for Systematic Reviews and Meta−Analyses (PRISMA) 
available at http://www.prisma−statement.org/. Since the available literature on the 
subject of the relationship between UCB and schizophrenia (SZ) isn’t overly vast, we 
considered as potentially eligible for this article any relevant studies published in 
English, regardless of date of publication, sample size, outcomes, comparators or length 
of follow−up. The studies which considered the role of UCB in CNS inflammation in 
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vivo and in vitro and/or the correlation between the levels of UCB or its oxidative 
metabolite biopyrrin and schizophrenia were included. The studies which only screened 
its samples for TB were not included, in order to keep this article focused. PubMed and 
Cochrane Library databases were used for the search as well as ClinicalTrials.gov. The 
search on the platforms was last done on 26/02/2018. The terms included were the 
truncated terms (bilirubin*[All fields] AND schizo*[All fields]). The research yielded 
75 results from PubMed and 15 from Cochrane Library; no results came up in 
ClinicalTrials.gov. After the inclusion of one extra paper (found in the bibliography of 
the above−mentioned articles) and the exclusion of case reports/duplicates/off−topic 
articles, 13 articles remained for inclusion in the review. Figure 2 resumes the articles 
selection process for review. 
 
 
Figure 2. Articles selection process for PRISMA review. 
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We found 3 studies reporting high levels of UCB in 26 Gunn rats, in vivo models of 
schizophrenia, and 10 studies reporting high levels of UCB in 473 human patients with 
schizophrenia. 
 
High levels of unconjugated bilirubin in vivo models of schizophrenia  
In the year of 1944, Gunn reported (Gunn 1944) a new type of mutant rats showing 
unconjugated hyperbilirubinemia and jaundice. The Gunn rats have since been used in 
several previous studies as the classic animal model of UCB encephalopathy (Rice et al 
2008). The homozygotic recessive jaundiced (j/j) Gunn rat have a congenital deficiency 
of the bilirubin liver conjugating enzyme UGT1A1, and consistently develops acute 
CNS dysfunction and kernicterus when given sulfadimethoxine (Rose et al 1979) or 
phenylhydrazine (Rice et al 2008). Hayashida et al. (Hayashida et al 2009) analyzed the 
behavioral changes induced by high serum UCB in the Gunn rat and considered the 
possibility of using it as new in vivo models for schizophrenia (Carpenter et al 2008). 
The animals used in the study were male hyperbillirubinemic j/j Gunn rats (with severe 
high levels of UCB), nonjaundiced +/j male Gunn rats (with non−severe high levels of 
UCB) and male Wistar rats. Several behavioral studies were carried out, in which 
certain specific actions (such as stretching, grooming, sniffing, and defecation, among 
others) and social interactions were counted during a specific amount of time in 
controlled environments (open field, home cage and new cage). In order to simulate 
environmental stress, the rats were exposed to 20 ms burst of white noise at 120 dB 
(pulse test) and 20 ms burst of white noise of 70 dB (70 prepulse + pulse test) followed 
by a 20 ms white noise burst at 120 dB or 20 ms white noise burst at 80 dB (80 prepulse 
+ pulse test) followed by a 20 ms white noise burst at 120 dB. Start response was 
measured using a startle reflex measurement system. Both Gunn j/j and +/j rats 
exhibited hyperlocomotion, a higher frequency of sniffing, and a lower frequency of 
defecation. These stereotypical behaviors (hyperlocomotion, continuous sniffing, 
licking, and gnawing) are thought to be animal equivalents of positive symptoms of 
schizophrenia (Nabeshima et al 1983). In the social interaction tests, frequently 
observed behaviors of Gunn j/j and +/j rats were attacking. Additionally, j/j rats showed 
impaired prepulse inhibition;  hypersensitivity to psychostimulants is suspected to be 
one of the features in SZ, and patients with SZ often perform poorly in prepulse 
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inhibition tests (Braff et al 1990) . In a follow−up study (Liaury et al 2012), Liaury et al. 
set out to examine the effects of UCB in the morphology of the microglial cells of Gunn 
rats. In it, the hippocampus Dentate Gyrus (DG) of 10 Gunn rats was compared with 
those of 10 Wistar rats. Microglial cells were marked with antibodies through 
immunohistochemistry;  rabbit anti ionized calcium binding adaptor molecule 1 (Iba1) 
and mouse antiCD11b were used. With light and confocal microscopy, Iba1−marked 
cells were found to have elongated cell somata with fewer branches but thicker 
processes in the hilus, subgranular zone (SGZ), granular layer (GL), and molecular 
layer (ML) of the hippocampus dentate gyrus. This type of morphology is known as 
activated morphology, a term that describes proliferating cells that demonstrate changes 
in their immunophenotype but have not undergone transformation into brain 
macrophages. Such a transformation can be stimulated by neuronal death but not by 
sublethal neuronal injury (Streit et al 1988). The ML cells showed small rod−shaped 
somata with numerous thin and highly ramified processes. This kind of morphology is 
known as ramified/resting morphology and is similar to the morphology found in Wistar 
rats. After counting the Iba1−labeled cell numbers, no significant difference between 
Gunn and Wistar rats in the estimated numbers of Iba1−labeled cells in all areas of the 
DG was found. Using a technique of electron microscopy, activated Iba1−labeled cells 
were shown to have an elongated cell body and enlarged cytoplasm. An organelle−rich 
cytoplasm that includes the Golgi apparatus, lysosomes, rough endoplasmic reticulum 
and some small vesicles containing low−density material was also observed. Next, the 
expression of a marker that increases during microglia activation, CD11b (integrin aM) 
(Sierra et al 2010), was examined. Microglial cells in Gunn rats were reported to 
express high levels of CD11b immunoreactivity, while microglial cells in Wistar rats 
did not show significant CD11b expression. Statistical analysis showed that areas of 
CD11b expression were significantly greater in Gunn rats than in Wistar rats in the hilus 
(p<0.005), SGZ (p<0.001), and GL (p<0.005). There was no significant difference of 
CD11b expression in the ML between Gunn rats and Wistar rats.  
We have discussed previously the activation of microglial cells and its role in CNS 
toxicity. This mechanism is a probable indicator of neurotoxicity and oxidative stress in 
the hippocampus. Indeed, significant reduction of hippocampal volume has been a 
frequent finding in both post−mortem and in vivo brain imaging studies (Shenton et al 
2001, Velakoulis et al 2006); it has also been suggested that SZ pathology could begin 
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with excitotoxic damage to the hippocampus (Schobel et al 2013). Tsuchie et al. 
published a study (Tsuchie et al 2013) which focused on the potential effects of 
antipsychotic therapy on the behavioral abnormalities of Gunn rats mentioned above. In 
this study, Gunn rats and Winstar rats (serving as the control group) were given 0.1 
mg/kg risperidone, 0.4 mg/kg aripiprazole, 0.2 mg/kg haloperidol or saline as control; 
the drugs were orally administered one day before the open−field and 
prepulse−inhibition tests and were continued for 14 days for the social interaction test. 
Six of each rat type (12 in total), were used in each medication group. Rats from each 
medication group were tested for their horizontal (ambulation) and vertical (rearing) 
locomotor activity in a novel environment (open−field test), their level and quality of 
social interaction when paired together in a single cage, and their startle response 
prepulse inhibition (with no stimulus, or 120 dB pulse of 20 ms duration, or 120 dB 
pulse preceded 100 ms by a 70 dB or 80 dB pulses of 20 ms in duration). In the 
open−field test, there was a significant difference between the Gunn Control (GC) 
group (10,595.4 ±964.3) and the Wistar rat control group (WC) (7988.0 ±1164.8) in the 
time spent in ambulation (p<0.05). The period of ambulation for the Gunn rat 
risperidone group (GR) (7341.8 ±1930.6) was significantly lower than that of the GC 
(p<0.05), and although there was no significant difference between the Gunn 
Haloperidol (GH) group (8740.7 ±1493.5) and the Gunn Aripiprazole (GA) group 
(9371.3 ±1869.5) and GC, there was a tendency for the activity of the GH and GA 
groups to be reduced. The activity of the Wistar rat medication groups (WM) was 
slightly decreased, but there was no significant difference between the WC and Wistar 
Medication (WR) groups (WR: 6812.5 ±1812.8; WH: 6563.2 ±900.4; WA: 6487.3 
±4056.4); there was also no substantial difference between the WC and Gunn rat 
medication groups. In rearing frequency, there was a significant difference between the 
GC (217.5 ±27.3) and WC (109.2 ±34.4) groups (p<0.01). The frequency of rearing by 
the Gunn rat medication groups (GR: 159.5 ±45.5; GH: 141.8 ±28.4; GA: 149.3 ±46.2) 
was significantly lower than those of the GC (p<0.01). There was no significant 
difference between the WC and Wistar rat medication groups (WR: 97.8 ±35.2; WH: 
70.2 ±30.6; WA: 100.7 ±55.3). The purpose of the open−field test was to measure 
behavioral changes when the animals were put in new environments. Exploratory 
activities increase when rats feel anxiety or fear or have problems of adaptation in new 
environments. SZ patients have a lower capability of adapting to their surroundings 
when placed in a foreign environment, and a subset of patients exhibits psychomotor 
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agitation; thus, increased locomotor activity might mimic this psychomotor agitation 
seen in humans with SZ (Powell et al 2006). Indeed, the activity of the GC group was 
increased compared with that of the WC group. Additionally, when the Gunn rats were 
given antipsychotics, their rearing activity was significantly decreased, implying a 
therapeutic effect of the drugs tested in the Gunn rat’s hyperactivity and ability to adapt. 
In the social interaction test, Gunn rats (49.0 ±15.9) exhibited significantly fewer social 
behaviors than the Wistar rats (236.2 ±37.8) (p<0.01) and also exhibited more antisocial 
behaviors (227.8 ±60.3) than the Wistar rats (8.8 ±8.9) (p<0.01). The social behaviors 
of the Gunn rat medication groups were increased (GR: 94.5 ±38.2;  GH: 74.8 ±30.5;  
GA: 93.2 ±38.0), and although the improvement in the Gunn rat social behavior after 
treatment with antipsychotics was not significant, the medication still tended to have a 
positive effect. The anti−social behaviors of the Gunn rat with medication groups were 
improved (GR: 187.8 ±60.3; GH: 180.7 ±37.9; GA: 157.0 ±39.1), and there was a 
significant difference between Gunn rat control group and medicated groups (p<0.01). 
The purpose of this test was to measure the decrease of motivation and social behaviors 
in rats, mimicking the behavior frequently seen in SZ patients. Antipsychotic drugs 
significantly improved Gunn rat’s anti−social behaviors. In the prepulse inhibition (PPI) 
test there was a significant difference between GC (13.2 ±21.2) and WC (40.3 ±28.9) 
(p<0.01) on the 70 dB prepulse test; although there was no significant difference 
between the GC and Gunn rat medication groups (GR: 20.3 ±27.0; GH: 25.0 ±9.2; GA: 
24.2 ±22.2), the Gunn rat PPI deficit tended to be ameliorated by the administered 
antipsychotics. In the 80 dB prepulse there was a significant difference between GC 
(43.7 ±13.9) and WC (77.1 ±8.2) (p<0.01), while there was a tendency for the PPI 
deficit of the Gunn rat medication groups to be inhibited (GR: 54.5 ±21.6; GH: 51.7 
±19.7; GA: 47.2 ±8.9). This study thus shows that antipsychotic medications affect 
Gunn rat behaviors in a similar way to SZ behaviors. The findings of this and of the 
previously mentioned studies suggest that the Gunn rat represents a promising new 
model for schizophrenia, and that this model might help further SZ investigation and the 
role of UCB in its pathogenesis. 
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High levels of unconjugated bilirubin in humans with schizophrenia  
A considerable number of published studies have demonstrated an increase in serum 
total bilirubin in patients with schizophrenia, but few have specified the correlation 
between the unconjugated form of the protein and SZ.  
In 1991, Muller et al. demonstrated a significantly higher incidence of 
hyperbilirubinemia in schizophrenics than patients suffering from other disorders 
(Muller et al 1991), being one if not the first study to propose a relationship between the 
molecule and the illness.  
Considering the specific correlation between UCB and SZ, there were few but 
interesting studies published. In 2000, Miyaoka et al. published a study (Miyaoka et al 
2000) tackling the association between Gilbert’s Syndrome (GS), a disease which 
courses with high plasma unconjugated bilirubin, and SZ. In the previous study, the 
plasma bilirubin concentration was collected from a sample of 290 patients admitted to 
the Department of Psychiatry at the Shimane Medical University, and the TB and CB 
levels were subsequently determined through the bilirubin oxidase method. UCB was 
calculated on the basis of the difference between both parameters. The patients were 
subdivided in 3 groups based on their diagnosis (ICD 10): schizophrenia (97 patients), 
affective psychosis (145 patients) and neurosis/personality disorders (48 patients). A 
total of 9% of all patients and 20.6% of schizophrenics were found to have elevated 
plasma bilirubin levels; the normal prevalence of GS in the general population is of 
2.4−7.0%. All schizophrenics with hyperbilirubinemia had an increased UCB, whereas 
CB was within the normal range. Statistically significant differences were found 
between patients with schizophrenia and affective psychosis (χ2=18.8, p < .0001), 
between those with schizophrenia and mania (χ2=3.991, p<0.0457), between those with 
schizophrenia and psychotic depression (χ2=15.66, p<0.0001), and between those with 
schizophrenia and neurosis/personality disorders (χ2=5.543, p<0.0186). The mean 
standard deviation (SD) plasma bilirubin level of schizophrenic patients with 
hyperbilirubinemia was 2.05 ±0.15 mg/dL. During hospitalization, hyperbilirubinemia 
decreased in 80% (N=16), fluctuated in 20% (N=4), and increased in 0% (N=0) of the 
20 patients receiving antipsychotic treatment. Of the schizophrenic patients with 
hyperbilirubinemia, 45% (N=9) had been drug−free for at least 6 to 8 weeks prior to 
their admission. Statistically, the schizophrenic patients with hyperbilirubinemia 
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showed a significant decrease in plasma bilirubin concentration during the course of the 
neuroleptic treatment. Next, the subgroup of SZ patients with hyperbilirubinemia had 
their psychiatric symptoms evaluated with the Positive and Negative Syndrome Scale 
(PANSS). Positive PANSS scores differed significantly between schizophrenic patients 
with and without hyperbilirubinemia (t=8.057, p<0.0001). Similarly, a significant 
difference was found between schizophrenic patients with and without 
hyperbilirubinemia on the general scores of the PANSS. However, no difference was 
found between SZ subjects with and without hyperbilirubinemia on the negative 
subscale. It’s important to note that this study did not have a healthy or non−psychiatric 
control group, which increases the risk of bias.  
In 2008, Japanese authors published a more in−depth study (Miyaoka et al 2008). In it, 
the team expanded their research on the same sample group using several imaging 
techniques and testing for clinical features through different scales. It again showed an 
increase in positive and Positive And Negative Syndrome Scale (PANSS) general 
scores in schizophrenia patients with idiopathic increased plasma UCB or GS during the 
acute phase of the psychotic episodes, when compared to those without GS. It also 
didn’t find a significant difference in negative scores between patients with and without 
GS in the acute phase. In the stable phases, however, it showed a relevant increase in all 
PANSS subscales scores in schizophrenics with GS compared to those without GS. 
Studying the brain morphology of all SZ patients via brain computed tomography (CT) 
scans, the same paper reported a diffuse enlargement of almost all internal and external 
components of cerebrospinal fluid (CSF) spaces in schizophrenia patients with GS 
relative to schizophrenia patients without elevated UCB and controls. The study also did 
a fluid−attenuated inversion−recovery magnetic resonance (FLAIR MR) analysis: axial 
5−mm−thick FLAIR MR Images from schizophrenia patients with GS (n=18) and 
schizophrenia patients without GS (n=18), all diagnosed according to Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition (DSM IV) criteria, were 
compared with age− and sex−matched non−psychiatric controls (n=18);  signal 
intensities in the hippocampus, caudate, thalamus, anterior cingulated gyrus, and insula 
were graded relative to cortical signal intensity in the frontal lobe. Compared to both 
schizophrenia patients without GS and normal controls, the schizophrenia patients with 
GS showed significantly increased signal intensities in almost all regions studied, 
suggesting specific changes in the fronto−temporal cortex, limbic system, and basal 
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ganglia. Lastly, in order to confirm this metabolic alteration, levels of N−acetylaspartate 
(NAA), choline (Cho), and myoinositol (ml) in the hippocampus, basal ganglia, 
Anterior Cingulate Gyrus (ACC), and insula of the cerebellum of schizophrenic patients 
with GS were analyzed through proton magnetic resonance spectroscopy (1H−MRS). 
According to the paper, the major finding was that SZ with GS, compared to both 
schizophrenics without GS and normal controls, showed significant decreases of 
NAA/Creatine (Cr) and ml/Cr in the hippocampus. In basal ganglia, the schizophrenics 
with GS, compared to normal controls, showed significant decreases of NAA/Cr and 
ml/Cr, and compared to schizophrenics without GS, showed significant decrease of 
ml/Cr. In the ACC, patients with schizophrenia and GS showed significant decreases in 
NAA/Cr, Cho/Cr, and ml/Cr compared healthy subjects and compared with 
schizophrenia without GS. In the Insular cortex, patients with schizophrenia and GS 
showed significant decrease in NAA/Cr, Cho/Cr, and ml/Cr compared with healthy 
subjects and compared with patients with schizophrenia without GS. Patients without 
GS also showed significant decreases in NAA/Cr, and Cho/Cr, and ml/Cr compared 
with healthy subjects. Assuming that NAA is a neuron number and/or viability marker, 
a decrease of NAA/Cr with schizophrenics with GS might suggest the effect of UCB on 
the structure and/or function of the hippocampus, basal ganglia, ACC, and Insular 
cortex. And a decrease of ml/Cr, as a glial marker and/or viability marker, in 
schizophrenics with GS might suggest the effect of UCB on the glial structure and/or 
function of the hippocampus.  
In 2010 Semnani et al. have published a study (Semnani et al 2010) in which 162 
patients with SZ, 155 patients with Bipolar Disorder (BD) type I and 95 patients with 
cardiac disease had their serum levels of TB and CB measured both at admission and at 
discharge, after receiving treatment. The initial mean TB level of SZ patients was in the 
normal range but significantly higher than BD patients and the same parameter was 
higher in BD patients than in the cardiac disease patients. All schizophrenic patients 
received antipsychotic medications, including haloperidol (100 patients), risperidone 
(53 patients), and clozapine (9 patients). 57 of BD patients also underwent antipsychotic 
therapy: (haloperidol, 42 patients), perphenazine (1 patient), and risperidone (14 
patients). The mean UCB level was decreased in all three groups at discharge (P0.05, 
R2=0.042, F(2.137)=2.9, p=0.05;  β=0.004, t(137)=0.042, p>0.05, R2=0.039, 
F(2.137)=2.79, p>0.05, respectively) and UCB levels (β=0.06, t(137)=0.680, p>0.05, 
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R2=0.039, F(2.137)=2.78, p>0.05;  β=0.01, t(137)=0.116, p>0.05, R2=0.036, 
F(2.137)=2.55, p>0.05, respectively). On comparing the paranoid SZ and non−paranoid 
SZ groups, the mean serum TB and UCB (in mg/dl) were significantly higher in the 
paranoid SZ (mean TB=0.60 ±0.43, t(69)=2.08, p=0.03;  mean UCB=0.44 ±0.43, 
t(69)=1.95, p=0.05) and non−paranoid SZ groups (mean TB=0.80 ±0.49, t(69)=2.76, 
p=0.03;  mean UCB=0.65 ±0.43, t(69)=2.99, p=0.004) compared with the BD group 
(mean TB=0.47±0.07, mean UCB=0.32±0.23), but there was no significant difference 
between the paranoid and non−paranoid SZ groups (mean TB=0.60±0.43 vs 0.8±0.48, 
t(69)=1.07, p=0.29;  mean UCB=0.44 ±0.43 vs 0.65 ±0.43, t(69)=1.11, p=0.26). As in 
the aforementioned research, there was no healthy or non−psychiatric control group in 
this study.  
A 2017 study (Gama Marques 2017) set out to evaluate whether high yet within normal 
range UCB levels could be considered a potential biomarker in the differentiation 
among acute psychotic patients with SZ, schizoaffective disorder and bipolar disorder 
(BD). Two hundred and four acute patients (50 with Z, 69 with schizoaffective disorder 
and 85 with BD) and 55 healthy controls were included. SZ patients presented higher 
UCB mean values (0.39 mg/dL, ±0.16 mg/dL), schizoaffective patients presented 
intermediate values for UCB mean values (0.36 mg/dL, ±0.13 mg/dL), and BD 
presented lower values for UCB mean values (0.29 mg/dL, ±0.13 mg/dL). A one−way 
Analysis of Variance (ANOVA) test was used to demonstrate a statistically significant 
difference (p≤0.0001) between mean values of UCB. On the post−hoc Bonferroni 
multiple comparison tests there was statistically significant difference between patients 
with SZ and BD (p≤0.0001) as well between schizoaffective and BD (p≤0.01). Both 
patients with SZ (p≤0.0001) and schizoaffective disorder (p≤0.01) showed statistically 
significant difference when compared with controls. A univariate corrected ANOVA 
model with age and gender as covariates was employed to test for possible bias; no 
influence was found.  
The reaction of bilirubin with ROS produces many kinds of biopyrrins, also known as 
bilirubin oxidative metabolites (BOMs). Yamaguchi et al. determined, in 1994, the 
chemical structures of two biopyrrins (biotripyrin−a and biotripyrin−b) purified from 
the urine of healthy volunteers (Yamaguchi et al 1994). Yamaguchi et al. reported in a 
later study (Yamaguchi et al 2002) that emotional stimuli are associated with an 
37 / 99 
 
increase in the BOMs in human urine, and thus could be useful markers of 
psychological stress. Following this logic, some studies have analyzed the urinary 
secretion of BOM’s in SZ patients in order to examine the antioxidative activity of 
bilirubin in this group. Miyaoka et al. (Miayaoka et al 2005), in a study in which 15 
acute SZ patients and 10 patients with depression (both groups diagnosed according to 
DSM IV) were compared with controls of 48 men and 48 women, found that mean 
levels of urinary BOMs in patients with schizophrenia and depression were significantly 
higher (11.3 ±7.1 and 4.74 ±1.1 μmol/g creatinine) than in healthy controls (2.5±1.3 
μmol/g creatinine). Moreover, the mean level of urinary BOMs in schizophrenic 
patients was significant higher than that in the depressed patients, and the level of 
urinary BOM’s showed correlations with Brief Psychiatric Rating Scale (BPRS) scores 
in SZ patients (r=0.671, p<0.0001). 
Yasukawa et al. (Yasukawa et al 2007) published a similar study, in which 15 SZ 
patients (diagnosed with DSM IV criteria) and 100 healthy controls (50 men and 50 
women) had their urinary levels of BOMs analyzed. They reported significantly higher 
urinary concentrations of BOMs in patients with diagnoses of schizophrenia on 
admission (15.9 ±8.2 μmol/g creatinine) compared to controls (2.2 ±1.3 μmol/g 
creatinine; p=0.0164). Response to treatment was associated with significant decreases 
in the concentration of BOMs.  
Miyaoka et al. (Miyaoka et al 2015) published a paper in which the urinary BOMs of 29 
SZ patients (DSM IV criteria) were compared with those of 30 healthy controls. The 
mean levels of urinary BOMs in patients with schizophrenia and normal controls were 
1.51 ±0.74 and 1.11 ±0.54 μmol/g creatinine, respectively;  the mean levels of urinary 
BOMs in patients with schizophrenia were significantly higher than those in the control 
subjects (p=0.019). The level of urinary BOMs showed a correlation with the duration 
of illness (r=−0.419, p=0.024) and with BPRS scores (r=0.583, p=0.001). The main 
findings of our review were chronologically gathered in Table 1. 
 
 




The topic of the correlation between unconjugated bilirubin and the incidence of 
schizophrenia cannot be said to be a completely new one; many studies have been made 
in order to elucidate this very specific aspect of a particularly complex disorder. The 
interest of this research lies mainly in the possibility of finding an objective, measurable 
and potentially influenceable parameter which could help complement the still 
somewhat subjective approach to the diagnosis, management and even prevention of 
schizophrenia. If this possibility turned out to be true, it would imbue medical 
professionals with a powerful weapon against SZ. Many studies have found a statistical 
relationship to exist between UCB and SZ. However, this link remains vague, as it is so 
far unclear if there is a solid causal connection and, if present, which is the precedent 
event. It is also uncertain whether there is a direct or inverse proportionality between the 
serum levels of UCB and the incidence of SZ. Some studies have reported an increased 
incidence of SZ with higher levels of UCB (Miyaoka et al 2000, Miyaoka et al 2008, 
Semnani et al 2010, Radhakrishnan et al 2011, Gama Marques et al 2017, Gama 
Marques et al 2019, Pradeep et al 2019), while others have reported the opposite: an 
increase in SZ among individuals with lower UCB levels (Yao et al, 2000, Vitek et al 
2010). Some studies showed a reduction in plasma TB levels with treatment (Miyaoka 
et al 2000, Semnani et al 2010), and some reported a correlation between symptomatic 
scales and plasma UCB concentrations (Miyaoka et al 2000, Miyaoka et al 2008, 
Semnani et al 2010). However, some studies reported an absence of significant effect of 
antipsychotic therapy on TB levels (Bach et al 2010, Radhakrishnan et al 2011). This 
could thus point to a non−linear, complex link between UCB and the pathophysiology 
of SZ, a hypothesis which certainly does not appear farfetched when one considers the 
complicated role of UCB in the antioxidant and inflammatory responses, as well as the 
multifactorial nature of SZ. As shown by various articles cited in this review, UCB has 
been linked to in vitro and in vivo neurotoxicity. It appears to have direct and indirect 
nefarious effects towards most (if not all) cell types in the CNS. The threshold above 
which UCB begins to lose its beneficial antioxidant effects on CSN cells appears to be 
rather small (Doré et al 1999), so that even small imbalances in the regulation of this 
molecule could potentially change its positive properties to deleterious ones. In both 
study groups – the studies which report a direct correlation between increased UCB 
levels and SZ incidence, and those which report an inverse correlation – the crux of the 
matter appears to be a dysfunction in the inflammatory mechanisms in the brain. When 
the concentration of plasma UCB is too high, it appears to directly cause 
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neuroinflammation, ROS production and cell apoptosis; when it is too low, however, it 
might impair the body’s antioxidative defenses and result also in increased 
inflammation and increased ROS levels. Therefore, UCB could be both the cause and 
the effect of the alterations seen in the schizophrenic patient.  
There currently are two main models used to explain the possible causes of 
schizophrenia. The neurodevelopmental model posits that SZ is the consequence of an 
anomaly in the developmental stages of the brain which leads to problems in acquiring 
cognitive skills (Bora et al 2014), a process that starts long before the onset of clinical 
symptoms (Rapoport et al 2012). The neurodegenerative model hypothesizes that the 
dysfunctional development is progressive and persists after the onset of the illness, 
resulting in structural changes in the brain; it involves a cytopathological process with 
loss of neurons and synapses and subsequent gliosis (Rund 2018). Additionally, some 
studies support the theory that the psychotic episode is, in itself, neurotoxic and 
contributes to the structural changes seen after the onset of the symptoms (Rund 2014). 
It appears plausible that the pathophysiology of SZ could be explained by a combination 
of these models; it could be seen as an early neurodevelopmental aberration exacerbated 
by a limited ongoing neurodegenerative process and/or by recurring neurotoxic 
psychotic episodes (Buoli et al 2017). UCB could potentially play different roles in 
these hypotheses. As previously stated, neurons previously exposed to elevated 
concentrations of UCB become more susceptible to further inflammatory damage and 
death by apoptosis, which could point to an early priming leading to faults later in life. 
A subsequent decrease in the cortical cytoarchitecture of mice previously exposed to 
high levels of UCB was also reported (Falcão et al 2007). Since neuritic breakdown is 
believed to underlie the clinical and cognitive symptoms of schizophrenia (Gilmore et al 
2004) and a decrease in cortical areas of the brains of SZ patients has been reported in 
the past (Haukvik et al 2013), this could signify that the progressive impairment of 
neuronal development by UCB might explain the proposed link between schizophrenia 
and hyperbilirubinemia. As shown above, UCB can also directly cause an inflammation 
reaction, and could be one of the main culprits of the neurodegeneration model. The 
lower UCB levels, reported by some studies, could indicate a chronic proinflammatory 
state caused by increased ROS and depletion of the antioxidant potential, thus leading to 
the progressive loss of neurons. However, some studies have shown a decrease of UCB 
levels in patients with previously high plasma UCB with the initiation of antipsychotic 
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treatment (Miyaoka et al 2000, Semnani et al 2010). The fluctuation of UCB 
concentrations – be it an increase or a decrease – could explain some of the mechanisms 
involved in the neurotoxicity of psychotic episodes. The study published by 
Radhakrishnan et al. (Radhakrishnan et al 2010) has the particularity of making a 
distinction between different types of SZ patients, comparing the UCB levels of 
paranoid schizophrenia patients with those of non−paranoid schizophrenia patients; 
however, it didn’t find statistically relevant differences between the two groups. The 
studies focused on the fluctuations of biopyrrin concentration are also potentially 
elucidating. As we have stated, biopyrrins are the product of the oxidation of UCB by 
ROS. We have also discussed how an elevation in UCB levels can independently cause 
the production of ROS. This could mean the existence of a buffer system of sorts 
between UCB and ROS: a surplus of UCB causes inflammation and ROS production, 
which in turn oxidizes UCB, decreasing its plasma concentration (Figure 2). Biopyrrins 
were found to be correlated with rating scores (Miyaoka et al 2005, Miyaoka et al 
2015), response to treatment (Yasukawa et al 2007) and duration of disorder (Miyaoka 
et al 2015). The variation in the oxidative metabolism of bilirubin logically indicates the 
differences in the antioxidant activity of the molecule. However, this could either mean 
an increased recruitment of healthy antioxidant defenses or the result of compensation 
by the UCB ROS buffer system previously discussed. In order to clarify this point, 
future studies should consider comparing mean plasma UCB levels with mean urinary 
excretion of biopyrrins in acute and chronic episodes.  
Also noteworthy are the comparisons between the bilirubin levels of schizophrenic 
patients and those of patients with bipolar disorder and schizoaffective disorder. Several 
studies showed higher UCB levels in schizophrenic patients when compared to bipolar 
ones (Semnani et al 2010, Radhakrishnan et al 2010, Gama Marques et al 2017, Pradeep 
et al 2019), and higher UCB levels among BD patients when compared to controls 
(Semnani et al 2010). The studies by Gama Marques et al. also showed higher UCB 
levels in patients with schizoaffective disorder when compared to BD (Gama Marques 
et al 2017, Gama Marques et al 2019). This could just be the translation of greater 
subjective stress among SZ patients. It could, nonetheless, be the evidence of a similar 
pathophysiological background between the diseases.  
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The DSM 5 criteria already consider the schizoaffective disorder as part of the 
schizophrenia spectrum. Additionally, some studies have reported a significant overlap 
in phenomenological, biological and genetic characteristics between SZ and BD (Potash 
2006, Potash et al 2009) suggesting that they could also represent different points in the 
same continuous pathological spectrum (Keshavan et al 2012). 
Figure 3 − UCB physiologic (left) and pathologic (right) metabolic pathways. 
  
43 / 99 
 
As we have seen, the evidence supporting the existence of a correlation between UCB 
and SZ is considerable. The vast majority of studies included in this review have 
managed to report a statistically relevant link between the two variables, thus making it 
possible for us to affirm that it seems very likely that UCB is in some way implicated in 
the pathology of SZ. However, there existed a discrepancy in the nature of this relation, 
with some studies claiming that SZ was correlated with higher levels of UCB and some 
claiming that SZ was linked with lower levels of the molecule. We didn’t see clear 
reasons why one hypothesis might be more probable than the other, be it biases, 
statistical errors, bad sample selection or others. Considering the complexity of SZ, we 
have conjectured that this association might be multi−factorial and non−linear, with 
UCB and the pathophysiology of SZ being mutually influenced by each other. In this 
more holistic hypothesis, SZ is viewed simultaneously as the cause and the effect of 
fluctuations in UCB levels and vice−versa, creating a vicious cycle that would 
perpetuate the symptoms of SZ. However, as of yet no studies have pointed 
unequivocally towards this answer. Maybe, as the research on the mechanisms and 
causes underlying SZ advances, we will better understand the role of UCB in this 
disease. In spite of the present lack of clarity, we believe there is a great potential in the 
research of UCB as a biological marker for management of SZ.  
UCB is likely implicated in many different stages of the progression of the illness. It 
could be responsible for making one’s nervous system more susceptible to 
neurodevelopmental faults, consequently qualifying its fluctuations as a promising risk 
factor. It seems to be linked with the acute phases of the disease, thus making it eligible 
as a possible tool for early diagnosis and subsequent follow−up. Finally, it appears to be 
intimately related to the subjective stress and the intensity of symptoms, therefore being 
a propitious guide for treatment selection or even a possible target for neuroprotective, 
antioxidant and anti−inflammatory adjunctive therapies for bilirubin−induced 
neurological dysfunction (Kapitulnik et al 2012) in schizophrenia and spectrum related 
disorders. We truly believe there will be, in a near future, interesting opportunities for 
research in this fascinating topic (Gama Marques et al 2018). 
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PERSONAL CONTRIBUTE FOR THE RESEARCH 
 
After dealing, at the emergency room, with a particular psychotic patient, with high 
levels of UCB, we started thinking that might be interesting looking back to psychotic 
patient’s laboratory records at our hospital. This work would result in various poster and 
oral communications presentations, in different scientific conferences, all around the 
world: Athens 2014, Lisbon 2015, Toronto 2015, Tokyo 2016, and Oxford 2016. 
After publishing the aforementioned case report in a journal dedicated to clinical 
neurosciences (Gama Marques 2017), we would manage to publish the preliminary 
results of our retrospective studies, in a psychiatric journal (Gama Marques et al 2017). 
Our next step would be the creation of a longitudinal study research protocol for the 
study UCB as a possible biomarker candidate in the schizophrenia psychosis spectrum. 
We were particulary interested, not only in the classic distinction between schizophrenia 
and bipolar disorder patients, but also in a possible difference among patients with 
schizophrenia and schizoaffective disorder. That effort would become our first 
perspective paper (Gama Marques and Arantes−Gonçalves 2018). 
Besides our clinical work we start, in an academic setting, supervising some master 
students. One of those would result in a review dedicated to the potential value of UCB 
for the diagnosis in the spectrum of schizophrenia disorders (Pommerening Dornelles et 
al 2019).  
In the meanwhile, we published the full report on our retrospective data, through a 
journal dedicated to international clinical psychiatry. That would be another step in our 
hypothesis direction: UCB might be a promising candidate biomarker, somehow useful 
for the clinical distinction of patients with schizophrenia from those with 
schizoaffective disorder (Gama Marques et al 2019). 
We felt that our findings deserved a conceptual framework, in order to clarify clinical 
and basic neurosciences important questions, such as finding biomarkers for 
schizophrenia spectrum related disorders. That was our goal with our latest paper, an 
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epistemological perspective on the schizophrenia – schizoaffective – bipolar spectrum. 
(Gama Marques and Ouakinin 2019). 
Although our research group contribution did replicate data from other human studies 
from different parts of the world we were particularly interested in adding new 
perspectives looking for the relation between UCB at a basic level and the clinical 
expression of the disorders in a translational approach.  
With that objective in mind we worked in our first longitudinal protocol. That included 
the assessment of UCB mean levels at two different occasions: during the psychiatric 
admission due to psychotic relapse, and at the outpatient follow−up appointment, twelve 
months after. For this particular study, besides classic psychopathological evaluation, 
we also included other important clinical variables such as psychossocial function and 
neuropsychological tests. We believe that our work opened already new avenues for 
future research: 
1. Gama Marques J, Ouakinin S. Schizophrenia − Schizoaffective − Bipolar disorder 
spectra: an epistemological perspective. CNS Spectr. 2019 Oct 28:1−5. doi: 
10.1017/S1092852919001408. Impact Factor 3.940, Quartile Q1. 
2. Gama Marques J, Arantes−Gonçalves F. A perspective on a possible relation 
between the psychopathology of the Schizophrenia/Schizoaffective spectrum and 
Unconjugated Bilirubin: a longitudinal protocol study. Front Psychiatry. 2018 Apr 
23; 9:146. doi: 10.3389/fpsyt.2018.00146. Impact Factor 3.161, Quartile Q1. 
3. Gama Marques J, Pedro I, Ouakinin S. Unconjugated bilirubin and acute psychosis: 
a five years retrospective observational and controlled study in patients with 
schizophrenia, schizoaffective and bipolar disorders. Int J Psychiatry Clin Pract. 
2019 Nov; 23(4):281−285. doi: 10.1080/13651501.2019.1638940. Impact Factor 
1.821, Quartile Q2. 
4. Gama Marques J, Ouakinin S. Clinical profile in schizophrenia spectrum: relation 
with unconjugated bilirubin and other psychophysiological features − a longitudinal 
exploratory study. CNS Spectrums. CNS Spectr. 2019 Dec 19:1−8. doi: 
10.1017/S1092852919001639. Impact Factor 3.940, Quartile Q1. 




Unconjugated bilirubin and acute psychosis: a five years retrospective 
observational and controlled study in patients with schizophrenia, schizoaffective 
and bipolar disorders. 
Our objective is to assess UCB levels as a possible biomarker for acute psychotic 
patients in the distinction among those with schizophrenia, schizoaffective and bipolar 
disorder.  
Our hypothesis is that UCB levels will be higher in patients with schizophrenia (ICD10, 
WHO, F20.X code) than in patients with bipolar disorder (ICD10, WHO, F31.X code) 
and that patients with schizoaffective disorder (ICD10, WHO, F25.X code) will have 
intermediate values between the other two groups. 
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Clinical profile in schizophrenia and schizoaffective spectrum: relation with 
unconjugated bilirubin in a prospective and controlled study with 
psychopathological and psychosocial variables. 
In this study our main objective is to assess patients suffering from acute psychosis, 
trying to understand if UCB mean levels may have any potential interest as a biomarker 
in both categorical nosological axis, e.g. schizophrenia (ICD 10, WHO, F20.X code)  
versus schizoaffective disorder (ICD 10, WHO, F25.X code) and a severity axis, e.g. 
relapse versus partial remission.  
Our first hypothesis (primary objective) is to test if UCB levels will be higher in 
patients with schizophrenia than in patients with schizoaffective disorder.  
Our second hypothesis (secondary objective) is to test if UCB levels will be higher 
during relapse (at ward admission) versus partial remission (at outpatient appointment), 








Unconjugated bilirubin and acute psychosis: a five years retrospective 
observational and controlled study in patients with schizophrenia, schizoaffective 
and bipolar disorders. 
For this study we used data collected during 5 years (from the beginning of 2011 until 
the end of 2015). At our psychiatric hospital all clinical files are easily accessible 
through a software interface exclusively used by physicians and blood sample analyses 
are usually taken on entrance to everyone admitted in our acute patient’s wards. All 
blood samples were taken in fasting individuals, with Monovette® vacuum system and 
Serum Gel Z/4.9mL Sarstedt® tubes. Serum was obtained by centrifugation and 
maintained in ambient temperature, and readily processed with ABX Pentra 400® 
Horiba Medical equipment. The total and conjugated bilirubin measurement was based 
on the diazotized 2,4−dichloroaniline method. Laboratory internal quality was assured 
by ABX Pentra Multical® and ABX Pentra N Controlo® calibrators. External quality of 
laboratory results quality was evaluated by Ricardo Jorge’s National Institute of Public 
Health. First we excluded all individuals with abnormal high values for TB, Aspartate 
transaminase (AST), Alanine transaminase (ALT), Gamma−glutamyltransferase (GGT), 
Lactate Dehydrogenase (LDH) or serologic signs of viral hepatitis type B (VHB) and\or 
viral hepatitis type C (VHC). We also excluded all patients with positive alcohol/drugs 
on blood/urine test. Secondly we checked all individuals’ clinical files, searching for 
psychiatric admissions and ICD10 psychiatric diagnosis obtained through routine 
clinical observation. We excluded all chronic patients admitted in long term 
rehabilitation wards. We also excluded patients with ICD10 diagnosis different than 
schizophrenia (not ICD 10, WHO, F20.X code), schizoaffective (not ICD 10, WHO, 
F25.X code) or bipolar disorder (not ICD 10, WHO, F31.X code). Individuals without 
known psychiatric diagnosis were our control group composed of healthy persons (most 
of them workers at our hospital) who did routine lab tests through occupational 
medicine services. Thirdly we calculated the UCB value as the subtraction difference 
between TB and CB of remaining patients. Simultaneously we calculated the average 
duration of admission, as a ratio of total number of days during admissions dividing by 
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the total number of admissions. Our final sample was composed by 4 different groups: 
SZ patients (ICD10 WHO F20.X code), schizoaffective patients (ICD10 WHO F25.X 
code), BD patients (ICD 10 WHO F31.X code) and general population healthy controls. 
Statistical analyses, Kolmogorov−Smirnov, post−hoc Bonferroni multiple comparison, 
one way and univariate corrected ANOVA were done using Statistical Package for the 
Social Sciences (SPSS) version 25. 
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Clinical profile in schizophrenia and schizoaffective spectrum: relation with 
unconjugated bilirubin in a prospective and controlled study with 
psychopathological and psychosocial variables. 
Our study was an observational longitudinal study, with two assessments in one year 
time−span (from thre beginning of 2016 until the beginning of 2017). The first 
assessment occurred during relapse of psychosis at the psychiatric ward admission and 
the second assessment during partial remission of psychosis at the outpatient 
appointment.  
Our inclusion criteria looked for all patients with acute psychosis under the diagnosis of 
SZ (WHO ICD10, F20.X code) or schizoaffective disorder (WHO ICD10, F25.X code), 
with age between 18 and 65 years old, admitted to our psychiatric ward.  
Exclusion criteria were hepatic, hemolytic or cholestasis related condition detected 
through blood sample analyses, as well as any important changes in AST, ALT, GGT 
and LDH values or positive tests for HVB or HVC infection. Substance related 
psychosis like cannabinoids, amphetamines, cocaine and heroin and psychoactive 
substances use was detected through urine sample analyses, for both assessments, 
yielding respective exclusion from study. Organic central nervous system disorder 
related psychosis was excluded in routine single computed tomography (CT) brain scan 
and/or routine repeated electroencephalography (EEG). As controls, we used admitted 
patients with acute bipolar disorder (WHO ICD10, F31.X code) paired for age and sex. 
All patients included were able to understand and sign informed consent. Scientific and 
Ethical approval was obtained at local boards, and investigation was developed 
according to the Declaration of Helsinki. 
Sociodemographic and clinical variables collected for our patients were age, gender, 
occupation, education years, smoking pack−year, use of contraceptive pill, body mass 
index, number of affected kin or Family Psychiatric History (FPH), years of duration of 
psychiatric disorder, years of Duration of Untreated Psychosis (DUP), days of Mean 
Length of Stay (MLS) at psychiatric ward and psychiatric medication, e.g. 
Chlorpromazine Equivalents (CPZE). 
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Biochemistry study included calculated UCB serum levels (UCB=TB – CB). Fasting 
blood samples were collected after a restful night and before breakfast, for both 
assessments, using vacuum S−Monovette® Serum Gel Z/4.9 ml (Sarstedt AG&Co) and 
our analytic method was 2,4−dicloroaniline photometry. Our laboratory used hardware 
system ABX Pentra 400® (Horiba Group) and software system was SISLAB® (Glintt). 
Psychopathological instruments used were Clinical Global Impression (CGI) for general 
clinical severity and PANSS (Kay et al 1987) for psychosis severity. The CGI measures 
symptom severity and it is widely used to measure treatment response and the efficacy 
of treatments in studies of patients with mental disorders. It is a 7−point scale that 
requires the clinician to rate the severity of the patient's illness at the time of 
assessment, relative to the clinician's past experience with patients who have the same 
diagnosis, with possible ratings from 1 “Normal, not at all ill” up to 7 “Among the most 
extremely ill patients”. The PANSS is a medical scale used for measuring symptom 
severity of patients with schizophrenia. It is widely used in the study of antipsychotic 
therapy and it is usually accepted as the golden standard that all assessments of 
psychotic behavioral disorders should follow. The patient is rated from 1 “absent” to 7 
“extreme” on 30 different symptoms based on the interview as well as reports of 
caretakers; therefore its total score ranges from 30 to 210. 
Psychosocial instruments used were Global Assessment of Functioning (GAF) (Endicott 
et al 1976) and Personal and Social Performance (PSP) (Morosini et al 2000) for social 
functioning assessment. GAF is a numeric scale used by mental health technicians to 
rate subjectively the social and occupational functioning of an individual, from 1 
“severely impaired” to 100 “extremely high functioning”. The PSP is a 100 points 
rating scale, with ratings being based mainly on the assessment of patient's functioning 
in four main areas: (a) “socially useful activities”;  (b) “personal and social 
relationships”;  (c) “self−care”;  and (d) “disturbing and aggressive behaviors”, on a 
six−point scale from “absent” to “very severe”.  
All scales used in our protocol were translated and validated for Portuguese language 
(Lima et al 2007, Higuchi et al 2014, Brissos et al 2012). 
For the schizophrenia and schizoaffective patients groups, all quantitative variables 
were summarized through descriptive statistics. This analysis included 
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socio−demographics characterization as well as the previously described biological, 
psychopathological and psychosocial variables.  
Statistical analyses with Kolmogorov−Smirnov, post−hoc Bonferroni multiple 
comparison, Student’s T−test, one way and univariate corrected ANOVA and linear 
regression models were done using Statistical Package for the Social Sciences (SPSS) 
version 25. 
Our complete protocol was discussed with international reviewers and is freely 
available online (Gama Marques and Arantes−Gonçalves 2018). Patient data collection 
is summarized in Figure 4. 
 
Figure 4 – UCB mean levels prospective study: patient data collection.  
  




Unconjugated bilirubin and acute psychosis: a five years retrospective 
observational and controlled study in patients with schizophrenia, schizoaffective 
and bipolar disorders. 
We were able to include 255 individuals, including 56 healthy controls and 199 acute 
patients (namely 44 with SZ, 99 with schizoaffective disorder and 56 with BD).  
Regarding gender characteristics of our sample 42% were males. The mean age was 
46.6 years old (±11.8 years old), ranging from 21 to 80 years old. The mean number for 
average duration of admission in the psychiatric ward for acute patients was 17.1 days 
(±18.2 days), ranging from 1 to 116 days. The individuals in the control group were 
excluded from this analysis.  
Schizophrenia patients presented lower mean age (41 years old), higher prevalence for 
male gender (62%), higher UCB mean values (0.41mg/dL, ±0.15 mg/dL) and higher 
average admission duration (29 days). Schizoaffective patients presented intermediate 
values for mean age (48 years old), male gender (52%), UCB mean values (0.34mg/dL, 
±0.12 mg/dL) and average admission duration (22 days). Bipolar patients presented the 
higher mean age (56 years old), lower prevalence for male gender (25%) as well as 
lower values for UCB mean values (0.28 mg/dL, ±0.12 mg/dL) and average admission 
duration (16 days). Figure 5 presents the difference between UCB mean levels among 
groups. 
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Figure 5 – UCB mean levels in groups of patients and healthy controls. 
 
Regarding UCB mean values, age and diagnosis: first we applied one sample 
Kolmogorov−Smirnov test to confirm normal distribution for age and UCB in the four 
groups (schizophrenia, schizoaffective, bipolar and controls). Then we applied one way 
ANOVA test to look for a statistically significant difference (p≤0.0001) between the 
mean values of UCB across the four groups. On the post−hoc Bonferroni multiple 
comparison test there was statistically significant difference in schizophrenia versus 
bipolar (p<0.001) and schizoaffective (p<0.03) as well in schizoaffective versus bipolar 
(p<0.04). There was no differences found between bipolar and control. Regarding a 
plausible bias on these results we applied a univariate corrected ANOVA model with 
age (p=0.6) and gender (p=0.2) as covariates, and found no influence. On Table 3 we 
represent our study’s main findings. 
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Schizophrenia 44 62 38 41 0.41a,b 29a 
Schizoaffective 99 52 48 46 0.34b,c 22 
Bipolar 56 25 75 56 0.28a,c 16a 
Control 56 23 77 56 0.28 − 
ap<0.001 bp<0.03 cp<0.04 
 
Regarding average admissions duration for the five year period and diagnosis: when 
applying a linear regression ANOVA model, with average admissions duration as a 
dependent variable we found statistically significant difference between schizophrenia 
versus bipolar (p<0.001) but there no statistically significant difference when comparing 
the average admissions duration between the other groups (e.g. schizoaffective versus 
bipolar, and schizoaffective versus schizophrenia). 
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Clinical profile in schizophrenia and schizoaffective spectrum: relation with 
unconjugated bilirubin in a prospective and controlled study with 
psychopathological and psychosocial variables. 
 
First assessment (relapse at ward admission) 
We had an initial number of 98 patients in our study: 48 with presumptive diagnosis of 
schizophrenia and 50 with presumptive diagnosis of schizoaffective disorder. We lost 
10 patients because of exclusion criteria: 5 had at least one blood sample positive for 
HVB and/or HVC infection; 3 had at least one urine sample positive for cannabinoids; 
and 2 had at least one EEG exam suggesting temporal lobe epilepsy. These excluded 
patients received new appropriate diagnosis and treatment and were referred to specific 
outpatient consultations after discharge from admission, namely gastroenterology, 
addiction and neurology services, respectively. The remaining 88 patients had no 
changes at all on their first blood and urine samples, EEG exam and CT brain scan, so 
they were included in our study for follow up. 
At the end of the first assessment (relapse; at ward admission) we included 88 patients 
(44 with confirmed diagnosed of schizoaffective disorder and 44 with confirmed 
diagnosis of schizophrenia). Although there was a higher prevalence of male patients in 
the group of patients with schizophrenia versus the group of patients with 
schizoaffective disorder, there was no statistically significant difference between 
groups. Other variables like age, education, family psychiatric history, smoking pack 
years and duration of untreated psychosis also didn’t show statistically significant 
differences between the two groups. No female patient was taking oral anti−conception 
pill during our study. General demographic data for the 88 patients that completed our 
first assessment is resumed in Table 4. 
Table 4: General Demographic Data (first assessment). 















Schizophrenia 44 61% 43.1±9.6 10.7±4.9 84 36 1±1 12.7±12.6 3.3±5.1 
Schizoaffective 44 39% 44.4±9.7 11.2±3.9 68 52 2±1 13.0±13.4 4.1±7.3 
FPH=Family Psychiatric History; SPY=Smoking Pack Years; DUP=Duration of Untreated Psychosis. 
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Regarding all clinical variables at first assessment (relapse; at ward admission) we did 
not find any statistically significant differences between patients with schizophrenia 
(N=44) and schizoaffective disorder (N=44). Patients with schizophrenia showed at 
admission higher mean PANSS values and also higher mean CPZE values, versus 
schizoaffective patients, but the difference had no statistical meaning. General clinical 
data for the 88 patients that completed our first assessment is resumed in Table 5. 
Table 5: Clinical Data (first assessment).  
 N CGI PANSS PSP GAF CPZE 
Schizophrenia 44 4.9±1.1 91.0±7.5 25.7±5.4 26.9±5.5 823±566 
Schizoaffective 44 5.0±0.9 87.1±11.7 30.6±9.1 31.0±8.1 655±455 
CGI=Clinical Global Impression;  PANSS=Positive And Negative Syndrome Scale;  PSP=Personal and Social Performance;  GAF=Global Assessment 
of Functioning;  CPZE=Chlorpromazine Equivalent. 
 
Regarding these 88 patients who completed the first assessment we compared 
(ANOVA) the mean UCB levels between our two groups (44 patients with 
schizophrenia and 44 patients with schizoaffective disorder) versus our control group 
(44 patients with bipolar disorder) and found a statistically significant difference 
(p=0.002). After performing Bonferroni post−hoc multiple comparisons we found 
statistically significant differences between the 44 patients from the group with 
schizophrenia and the other two groups, namely the 44 patients from the group with 
schizoaffective disorder (p=0.05) and the 44 patients from the control group with 
bipolar disorder (p=0.05). We found no statistically significant difference between the 
three groups for other variables such as sex, age or mean length of stay at the 
psychiatric ward (Table 6). 









Schizophrenia 44 61% 43.1±9.6 22.4±21.1 0.38±0.18ab 
Schizoaffective 44 38% 44.4±9.7 20.5±14.8 0.30±0.13a 
Bipolar 44 31% 47.4±11.0 17.2±14.0 0.27±0.13b 
MLS=Mean Length of Stay; UCB=Unconjugated Bilirubin; ap=0.05; bp=0.05 
 
Regarding correlations between psychopathological, psychosocial scales and laboratory 
data on patients who completed the first assessment (N=88), we only found a positive 
correlation (Pearson’s r=0.314; p=0.01) between UCB mean levels and PSP item (d) 
“disturbing and aggressive behaviors”. When looking for linear regression models for 
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UCB and all other variables, separately among the two groups of patients 
(schizophrenia and schizoaffective disorder) we were able to find a positive correlation 
(R2=0.223), with statistically significance (p=0.008), between the UCB mean level at 
first assessment (admission) in patients with schizoaffective disorder who completed 
full protocol (N=30) and mean length of stay (Figure 6).  
Figure 6 – Linear Regression: UCB at first assessment and MLS in schizoaffective 
disorder (p=0.008). 
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Second assessment (partial remission at outpatient appointment). 
From the 88 patients initially included in our study (44 with diagnosis of schizophrenia 
and 44 with diagnosis of schizoaffective disorder) we lost 28 patients: 22 quit the study 
before doing the second assessment (outpatient appointment); 3 died (stroke, acute renal 
failure and suicide by hanging); 2 traveled to live in another country and 1 was arrested 
for criminal behavior. The remaining 60 patients had no changes at all on at least two 
blood and two urine samples, two EEG exams and one CT brain scan so they were 
included on the final phase of data analysis. 
Although there was a higher prevalence of male patients in the group of patients with 
schizophrenia versus the group of patients with schizoaffective disorder, there was no 
statistically significant difference. Other variables like age, education, Family 
Psychiatric History (FPH), Smoking Pack Years (SPY) and Duration of Untreated 
Psychosis (DUP) didn’t show statistically significant difference between the two 
groups. The Median Follow-up (MFU) time for all sample (N=60) was 398±164 days; 
namely 392±159 days for patients with schizophrenia (N=30) and 405±172 days for 
patients with schizoaffective disorder (N=30), without statistically significant 
difference. Although we found a male gender prevalence among patients with 
schizophrenia there was no statistical significant difference when compared with 
patients with schizoaffective disorder. General demographic data for the patients that 
completed full protocol (both first and second assessment) versus patients who were lost 
to follow−up, is resumed in Table 7. 
Table 7: General Data (second assessment). 

















Schizophrenia 30 63% 43.8±9.5 10.0±5.2 87 37 1±1 14.9±13.1 2.9±4.9 392±159 
Schizoaffective 30 30% 45.5±9.0 11.3±3.8 70 57 2±1 12.9±13.1 3.8±6.2 405±172 
Lost Patients 28 63% 41.8±9.7 11.5±3.9 54 50 2±1 12.8±14.8 2.7±4.8 − 
FPH=Family Psychiatric History; SPY=Smoking Pack Years; DUP=Duration of Untreated Psychosis; MFU=Median Follow−up 
 
We found clinical improvement between the first assessment (relapse at ward 
admission) and second assessment (partial remission at outpatient appointment) for 
psychopathological (CGI and PANSS) and psychosocial scales (GAF and PSP). We 
found a statistically significant difference (p<0.0001) between the first assessment 
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(relapse at ward admission) and second assessment (relapse at ward admission) on both 
groups (schizophrenia, N=30); and schizoaffective disorder, N=30) for 
psychopathological (CGI and PANSS) and psychosocial scales (GAF and PSP). Both 
groups of patients (schizophrenia and schizoaffective disorder) showed a statistically 
significant clinical (CGI and PANSS) and functional (PSP and GAF) improvement from 
first assessment during admission until the second admission at outpatient appointment. 
Nevertheless there were no statistically significant differences among patients with 
different diagnosis (schizophrenia vs. schizoaffective disorder). General clinical data for 
the patients that completed full protocol, both first and second assessment, is resumed 
(Table 8). 
Table 8: General Clinical Data, Paired Samples T−test (first and second assessments) 
 N CGI1 CGI2 PANSS1 PANSS2 PSP1 PSP2 GAF1 GAF2 
Schizophrenia 30 4.9±1.1a 3.4±1.0a 91.0±7.5b 80.6±8.6b 25.7±5.4c 53.8±13.9c 26.9±5.5d 49.6±12.9d 
Schizoaffective 30 5.0±0.9 e 3.5±1.1 e 87.1±11.7f 79.6±8.3f 30.6±9.1g 51.2±19.6g 31.0±8.1h 49.8±18.6h 
CGI=Clinical Global Impression; PANSS=Positive And Negative Syndrome Scale; PSP=Personal and Social Performance; GAF=Global Assessment 
of Functioning; abcdefgh p<0.0001 
 
Regarding these 60 patients who finished our full protocol we compared (ANOVA) the 
mean UCB levels at the first assessment between the two groups (schizophrenia, N=30;  
and schizoaffective disorder, N=30) and the control group (bipolar disorder, N=30) and 
found a statistically significant difference (p=0.006). After performing a Bonferroni 
post−hoc multiple comparison, we found statistically significant difference between the 
first assessment (relapse at ward admission) of patients with schizophrenia (N=30) and 
the unique assessment (relapse at ward admission) of patients with bipolar disorder 
(N=30) (p=0.05). 
Regarding these 60 patients who finished our full evaluation protocol we compared the 
mean UCB levels at the second assessment (outpatient appointment) between the two 
groups (schizophrenia, N=30; and schizoaffective disorder, N=30; ANOVA) and found 
a statistically significant difference (p=0.006). After performing a Bonferroni post−hoc 
multiple comparison we found statistically significant difference between the second 
assessment (partial remission at outpatient appointment) of the 30 patients with 
schizophrenia and the second assessment (partial remission at outpatient appointment) 
of the 30 patients with schizoaffective disorder (p=0.05). Performing a paired samples 
T−test for these 60 patients from the two groups who completed the full protocol, we 
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only found a statistically significant difference between the UCB mean levels at the first 
assessment (relapse at ward admission) and the UCB means levels at the second 
assessment (partial remission at outpatient appointment) in the group of 30 patients with 
schizoaffective disorder (p=0.034).  














Schizophrenia 30 63% 43.8±9.5 23.3±24.5 37.0±27.9 0.38±0.19a 0.34±0.16b 
Schizoaffective 30 30% 45.5±9.0 20.5±12.2 35.1±23.7 0.31±0.14c 0.25±0.10bc 
Bipolar Control 30 46% 49.3±11.2 17.2±15.2 − 0.25±0.14a − 
MLS=Mean Length of Stay; UCB=Unconjugated Bilirubin; ap=0.05;  bp=0.05;  cp=0.034 
 
Looking at correlations between psychopathological, psychosocial scales and laboratory 
data on patients who completed the second assessment (N=60), we only found a 
negative correlation between UCB mean levels and PANSS item G7 “psychomotor 
retardation” (Pearson’s r=−0.399; p=0.002). 
Laboratory data is resumed for bilirubins (Table 10), liver function (Table 11) and 
metabolic syndrome (Table 12). There were no statistically significant differences for 
all these variables, except for the already mentioned UCB mean levels between first 
(relapse at ward admission) and second assessment (partial remission at outpatient 
appointment), among patients with schizoaffective disorder. 
 















Schizophrenia 30 0.38±0.19 0.34±0.16 0.16±0.06 0.18±0.06 0.54±0.23 0.52±0.21 
Schizoaffective 30 0.31±0.14a 0.25±0.10a 0.14±0.06 0.17±0.05 0.44±0.17 0.42±0.12 



















Schizophrenia 30 21.2±9.0 26.2±20.2 23.1±10.5 21.8±10.8 22.0±7.7 24.93±16.64 
Schizoaffective 30 24.1±14.7 26.8±16.4 24.1±13.5 22.3±10.7 47.6±124.9 50.73±91.42 
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Schizophrenia 30 24.7±5.8 194.0±33.6 202.9±41.9 114.5±48.2 142.9±91.2 96.3±13.5 100.4±19.8 
Schizoaffective 30 26.3±5.6 196.8±34.3 203.3±35.2 127.5±65.7 191.3±196.2 99.5±20.1 105.4±33.0 
BMI=Body Mass Index; Col=Cholesterol; TAG=Triacylglyceride; BGL=Blood Glucose Level. 
 
Regarding other laboratory parameters (Table 13), we only found a statistically 
significant difference (p=0.033) between Creatine Kinase (CK) mean levels in patients 
with schizophrenia with higher levels at first assessment (relapse at ward admission) 
213.0 ±297.2 mg/dL versus second assessment (partial remission at outpatient 
appointment) 106.5 ±74.4mg/dL. 
 
Table 13: Other laboratory data, Paired Samples T−test (first and second assessment). 
  N CPR1 CPR2 LDH1 LDH2 CK1 CK2 
Schizophrenia 30 0.53±0.60 0.54±0.82 184.3±41.7 172.3±29.2 213.0±297.2a 106.5±74.4a 
Schizoaffective 30 0.38±0.49 0.44±0.60 192.8±42.3 194.3±57.1 253.3±467.1 194.1±381.6 
CPR=C−Reactive Protein; LDH=Lactate Dehydrogenase; CK=Creatine Kinase. ap=0.033 
 
 
Using paired samples Student’s T−test for comparison between first and second 
assessment we found no statistically significant difference regarding PANSS positive 
symptoms, both in patients with schizophrenia and schizoaffective disorder (Table 14). 
On the other hand we found some statistically significant decrease regarding PANSS 
negative symptoms, when comparing the first assessment versus second assessment in 
patients with schizophrenia namely for itens N5 “difficulty in abstract thinking” 
(p=0.007), N6 “lack of spontaneity and flow of conversation” (p=0.03), N7 “stereotyped 
thinking” (p=0.002), and NTotal (p=0.01) (Table 15).  
We found some statistically significant decrease regarding PANSS negative symptoms, 
when comparing the first assessment versus second assessment in patients with 
schizoaffective disorder namely for itens N3 “poor rapport” (p=0.009), N5 “difficulty in 
abstract thinking” (p=0.011), and N7 “stereotyped thinking” (p=0.003) (Table 15). 
We found some statistically significant decrease regarding PANSS general symptoms, 
when comparing the first assessment versus second assessment in patients with 
schizophrenia namely for item G1 “somatic concern” (p=0.01) (Table 16), G9 “unusual 
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thought content” (p=0.0001), G10 “disorientation” (p=0.002), G11 “poor attention” 
(p=0.004), G12 “lack of judgment and insight” (p=0.003) and G15 “preoccupation” 
(p=0.001) (Table 17). 
We also found some statistically significant decrease regarding PANSS general 
symptoms, when comparing the first assessment versus second assessment in patients 
with schizoaffective disorder for item G3 “guilt feelings” (p=0.005) (Table 16), G9 
“unusual thought content” (p<0.0001), G12 “lack of judgment and insight” (p=0.011), 
and G15 “preoccupation” (p=0.016) (Table 17). 
Using paired samples Student’s T−test for comparison between first and second 
assessment we found no statistically significant difference regarding most of the 
neuropsychological tests. 
Nevertheless we found some statistically significant increase regarding TMTA 
(p=0.09), TMTB (p=0.009) (Table 18), MOCA item l “language” (p=0.043), and 
MOCA item o “orientation” (p=0.006) (Table 19), plus a statistically significant 
decrease in MOCA item n “naming” (p=0.09) (Table 19) in patients with schizophrenia.  
Finally, we found some statistically significant increase regarding WMS item bds 
“backward digit span” (p=0.03) (Table 18) and MOCA item l “language” (p=0.026) 





Table 14: PANSS’ Positive Symptoms Scale Data (Paired Samples T−Test)  
 N P1_1 P1_2 P2_1 P2_2 P3_1 P3_2 P4_1 P4_2 P5_1 P5_2 P6_1 P6_2 P7_1 P7_2 Ptotal1 Ptotal2 
Schizophrenia 30 5.1±1.2 3.5±1.2 3.0±0.9 2.4±0.6 3.8±1.3 2.7±0.9 2.3±0.8 2.3±0.5 3.5±1.3 2.6±0.9 4.3±1.4 3.3±1.0 2.2±0.6 2.2±0.5 24.3±3.8 19.0±3.8 
Schizoaffective 30 5.0±1.3 3.1±1.4 3.0±1.0 2.6±0.8 3.5±1.5 2.5±0.8 2.5±0.9 2.7±0.8 3.6±1.3 2.7±0.9 4.3±1.4 3.0±1.0 2.2±0.9 2.4±0.6 24.1±5.2 19.0±3.9 
 
 
Table 15: PANSS’ Negative Symptoms Scale Data (Paired Samples T−Test)  
 N N1_1 N1_2 N2_1 N2_2 N3_1 N3_2 N4_1 N4_2 N5_1 N5_2 N6_1 N6_2 N7_1 N7_2 Ntotal1 Ntotal2 
Schizophrenia 30 3.4±1.0 3.0±0.9 2.9±0.7 3.0±0.4 2.8±0.6 2.8±0.5 2.9±0.7 3.0±0.6 3.8±1.1a 3.3±1.1a 2.5±0.7b 2.4±0.6b 2.9±0.7c 2.4±0.5c 21.2±3.2d 19.9±2.9d 
Schizoaffective 30 2.9±0.8 3.0±0.7 2.6±0.7 2.8±0.6 2.5±0.6e 2.9±0.6e 2.7±0.6 2.8±0.5 3.4±1.2f 2.8±0.9f 2.3±0.8 2.4±0.6 2.8±0.6g 2.3±0.5g 19.1±3.3 19.1±2.7 
ap=0.007;  bp=0.03;  cp=0.002;  dp=0.01;  ep=0.009;  fp=0.011 ;  gp=0.003 
 
 
Table 16: PANSS’ General Symptoms Scale Data, Part 1 (Paired Samples T−Test)  
 N G1_1 G1_2 G2_1 G2_2 G3_1 G3_2 G4_1 G4_2 G5_1 G5_2 G6_1 G6_2 G7_1 G7_2 G8_1 G8_2 
Schizophrenia 30 3.2±1.0a 2.8±0.8a 2.4±0.7 2.4±0.6 2.5±0.8 2.3±0.7 2.5±0.6 2.6±0.7 2.2±0.7 2.5±0.7 2.4±0.8 2.4±0.6 2.5±0.7 2.5±0.6 2.3±0.9 2.1±0.4 
Schizoaffective 30 2.9±0.9 2.9±0.5 2.8±1.1 2.5±0.7 2.7±1.0b 2.3±0.5b 2.5±0.9 2.5±0.7 2.0±0.6 2.3±0.5 2.3±0.8 2.3±0.6 2.2±0.8 2.5±0.7 2.3±1.1 2.2±0.6 
ap=0.01;  bp=0.005 
 
 
Table 17: PANSS’ General Symptoms Scale Data, Part 2 (Paired Samples T−Test)  
 N G9_1 G9_2 G10_1 G10_2 G11_1 G11_2 G12_1 G12_2 G13_1 G13_2 G14_1 G14_2 G15_1 G15_2 G16_1 G16_2 Gtotal_1 Gtotal_2 
Schizophrenia 30 4.4±1.1a 3.5±1.2a 3.0±1.1b 2.5±0.7b 3.1±0.8c 2.7±0.6c 4.7±1.3d 3.8±1.2d 2.1±0.4 2.1±0.3 2.2±0.5 2.1±0.3 3.2±0.7e 2.6±0.7e 2.8±0.8 2.8±0.8 45.5±4.3 41.8±4.5 
Schizoaffective 30 4.1±1.4f 3.1±1.1f 2.7±1.1 2.6±0.9 2.9±1.3 2.9±0.7 4.2±1.5g 3.5±1.0g 2.0±0.3 2.2±0.6 2.5±1.0 2.5±0.7 3.1±0.8h 2.7±0.7h 2.5±0.7 2.5±0.6 43.8±6.1 41.5±4.2 
ap=0.0001; bp=0.002; cp=0.004; dp=0.003; ep=0.001; fp<0.0001; gp=0.011; hp=0.016 
 
 
Table 18: Neuropsychological Scales Data, Part 1 (Paired Samples T−Test) 
 N WMSfds1 WMSf±2 WMSbds1 WMSbds2 TMTA1 TMTA2 TMTB1 TMTB2 
Schizophrenia 30 6.6±1.5 6.7±1.9 3.5±1.3 3.4±0.9 82.3±53.8a 72.3±39.7a 183.2±93.1b 153.4±77.1b 
Schizoaffective 30 6.5±1.2 6.9±1.2 3.1±1.0c 3.4±1.1c 92.1±62.7 80.3±47.9 168.0±85.2 155.6±83.8 
WMS=Wechsler Memory Scale; TMT=Trail Making Test; ap=0.09; bp=0.009; cp=0.03 
 
 
Table 19: Neuropsychological Scales Data, Part 2 (Paired Samples T−Test) 
 N MOCAve1 MOCAve2 MOCAn1 MOCAn2 MOCAat1 MOCAl1 MOCAl2 MOCAab1 MOCAab2 MOCAdm1 MOCAdm2 MOCAo1 MOCAo2 MOCAtotal1 MOCAtotal2 
Schizophrenia 30 3.3±1.0 3.3±1.0 2.0±0.8a 1.9±0.6a 4.0±1.5 2.1±0.8b 2.3±0.7b 1.4±0.7 1.5±0.7 0.7±1.1 0.4±1.1 4.5±1.3c 5.4±1.3c 18.2±5.3 18.8±4.9 
Schizoaffective 30 3.3±1.3 3.3±1.1 1.8±0.7 2.1±0.7 4.1±1.9 2.0±0.8d 2.4±0.8d 1.5±0.6 1.4±0.7 0.7±1.1 0.6±1.2 5.0±1.1 5.3±1.1 18.4±5.4 19.2±5.2 






Unconjugated bilirubin and acute psychosis: a five years retrospective 
observational and controlled study in patients with schizophrenia, schizoaffective 
and bipolar disorders. 
UCB mean levels are clearly higher in patients with acute psychotic episodes of the 
schizophrenia and schizoaffective spectrum, when compared with bipolar patients and 
healthy controls. This UCB mean results were statistically independent from age, 
gender and correlated with the average duration of admission. We are not aware of 
previous studies reporting neurotoxic effect of normal level UCB. Thus our findings 
suggesting a possible correlation between clinical profile and UCB levels could be of 
interest as they open new possibilities of neurotoxicity research, even in patients with 
UCB normal levels. Our study cannot determine a causal relationship between higher 
level of UCB and psychosis. Indeed UCB level may be cause or consequence of a 
psychotic state. This is another one of the highlights of our study that can be used for 
further and future investigations. Our results are similar to those already described 
before (Semnani et al 2010, Radhakrishnan et al 2011, Gama−Marques et al 2017, 
Pradeep et al 2019) where patients with schizophrenia had significantly higher UCB 
levels  than bipolar patients, although all patients of our sub−groups were in normal 
range for (unconjugated, conjugated and total bilirubin values).  
Other important aspect of our results is that acute schizoaffective patients stand right in 
between the patients with schizophrenia and the patients with bipolar disorder. 
Schizoaffective patients seem to be, not only clinically speaking, but also regarding this 
specific biomarker candidate, somewhere between patients with schizophrenia and 
patients with bipolar disorder. 
This data reinforces the theory that schizoaffective disorder, might be an intermediate 
clinical entity, so often misunderstood but somewhere in between the schizophrenic and 
the bipolar spectra, both in phenotypic and physiopathologic aspects. 
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Some limitations of our methodology include the non−longitudinal design without 
randomization of sample, as well the absence of individual pairing with the healthy 
controls group. We are also aware about the high proportion of schizoaffective patients 
in our sample which may represent a result of instability in clinical diagnosis, an 
important bias in this kind of retrospective studies. For instance, it would have been 
interesting to see individual standardized assessment (e.g. CGI or PANSS) or whether 
bipolar patients with a manic episode showed differences from other patients. 
Unfortunately we didn’t have the opportunity to check some social reasons for each 
patient admission nor exclude social factors that may have influenced the duration of 
each admission. Last but not least our study didn’t control for medications influence on 
the assessed variables. 
Although our study is the first one suggesting a possible positive correlation between 
higher yet normal UCB mean levels and acute admission duration of psychotic patients 
with schizophrenia, schizoaffective and bipolar disorders, we are aware that more and 
better clinical studies are necessary to clarify these findings. 
Indeed we cannot conclude that normal level of UCB can be neurotoxic and lead to 
acute psychosis, our work suggests a possible relation between UCB mean levels and 
psychosis severity. Thus we believe that UCB mean levels in normal range, deserves 
further investigation in psychotic patients or animal models of psychosis. Our work also 
opens a possibility for UCB mean levels as a predictor on both psychosis type diagnosis 
(schizophrenia vs. schizoaffective vs. bipolar) and psychosis severity (duration of 
admission). However, more powerful studies shall be further conducted to clarify the 
relation between UCB levels and acute psychotic states. In our future studies we intend 
to study the longitudinal correlation of UCB mean levels in psychotic patients with a 
standard assessment protocol that shall include neuroimaging, neurophysiology, 
psychopathological, neuropsychological and psychosocial variables. These variables are 
quite important for the diagnosis and prognosis of the patients and this kind of work 
might become quite relevant for a better understanding of the etiology of psychotic 
disorders of the schizophrenia and schizoaffective spectrum (Gama Marques and 
Arantes−Gonçalves 2018).  
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Clinical profile in schizophrenia and schizoaffective spectrum: relation with 
unconjugated bilirubin in a prospective and controlled study with 
psychopathological and psychosocial variables. 
Our study results suggest that both of our experimental hypotheses might be true. 
Firstly, we confirmed that UCB mean levels are statistically significantly higher 
(p=0.05) in relapsing psychotic patients with schizophrenia (N=44; 0.38±0.18 mg/dL) 
than in relapsing psychotic patients with schizoaffective disorder (N=44; 0.30±0.13 
mg/dL). This outcome gives us some insight on the possible role of UCB as a biomarker 
for categorical distinction between schizophrenia and schizoaffective disorder, during 
an acute psychotic state, as described in our previous works. We also confirmed that 
UCB mean levels are statistically significantly higher (p=0.05) in remitting patients 
with schizophrenia (N=30; 0.34 ±0.16 mg/dL) than in remitting patients with 
schizoaffective disorder (N=30; 0.25 ±0.10 mg/dL). This outcome gives us some insight 
on the possible role of UCB as a biomarker for categorical distinction between 
schizophrenia and schizoaffective disorder, during the partial remission of an acute 
psychotic state, and that is, to our knowledge, the first time this kind of data is 
published. Secondly, we confirmed that UCB mean levels are higher in patients with 
schizophrenia (N=30) on relapse (0.38±0.19 mg/dL) versus partial remission (0.34±0.16 
mg/dL). We hipothezize that the absence of any statistically significant difference, for 
schizophrenia patients, may be simply due to the small sample size. Nevertheless we 
confirmed that UCB mean levels are statistically significantly higher (p=0.034) in 
patients with schizoaffective disorder (N=30) on relapse (0.31 ±0.14 mg/dL) than in 
partial remission (0.25 ±0.10 mg/dL), and that is, to our knowledge the first time this 
kind of data is published. This outcome gives us some insight on the possible role of 
UCB as a biomarker for a dimensional distinction in schizoaffective disorder. 
Besides our main objective we were also able to notice new interesting findings. We 
found, for the first time, through a linear regression model applied separately for 
patients with schizophrenia and patients with schizoaffective disorder, a statistically 
significant (p=0.008) positive correlation (R2=0.223) between UCB mean levels at 
admission and Mean Length of Stay (MLS) in patients with schizoaffective disorder 
(N=30) suggesting that UCB may have a potential role as a biomarker for admission 
duration, which is widely accepted as a indirect indicator of psychosis severity. Our 
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study was the first one to date, to our knowledge, looking for a correlation between 
UCB mean levels and psychosocial performance (GAF and PSP). Although we did not 
found any correlation between UCB mean levels and GAF scale, we were able to 
describe, for the first time, a positive Pearson’s correlation (r=0.314) with significant 
statistically meaning (p=0.01), between UCB mean level of relapsing patients (N=88) at 
the first assessment (admission) and one of the four items of PSP, the PSP item (d) 
“disturbing and aggressive behaviors”. Last but not least we have also found a new 
negative Pearson’s correlation (r=−0.399), with significant statistically meaning 
(p=0.002), between the UCB mean level of remitting patients (N=60) at the second 
assessment (outpatient appointment) and one of the thirty items on PANSS item G7 
“psychomotor retardation”. 
Interestingly enough, these two outcomes bring new insight to a new role of UCB level 
as a eventual biomarker for psychomotor agitation, both in the categorical spectrum 
(schizophrenia and schizoaffective disorder) and the severity spectrum (relapse at 
admission and partial remission at outpatient appointment).  One could say that 
psychomotor agitation could be causing changes in UCB levels, but that hypothesis is 
clearly excluded as we found no Pearson’s correlation between hemolysis biomarkers 
(e.g. LDH) and rhabdomyolysis biomarkers (e.g. CK). The statistically significant 
decrease (p=0.03) of CK levels in patients with schizophrenia (N=30) from the first 
assessment (213.0 ±297.2 mg/dL) to the second assessment (106.5 ±74.4 mg/dL) seem 
to be an independent epiphenomenon, probably secondary to the expected clinical 
improvement on psychomotor agitation but not contributing at all to the already 
mentioned Pearson’s correlations. 
Nevertheless we acknowledge other issues that should be discussed in all subjects 
included in our study: it would be important to have genetic tests in order to exclude 
GS; CSF analysis to exclude encephalitis; a more specific EEG analysis; more sensitive 
and specific brain scans, such as FLAIR MRI or even 1H−MRS for a better comparison 
of our data with other previous studies.  
Although our study suggests a possible role of higher, yet normal, UCB mean levels as 
a risk factor for psychotic relapse, we are much aware that more and better clinical 
studies are necessary to clarify these findings. 
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UCB serum level as a good biomarker candidate with diagnostic, nosological and 
categorical potential, for distinction between groups of patients with different 
psychotic disorders (schizophrenia or schizoaffective disorder) 
All our results suggest that UCB serum levels may be a useful biomarker in the 
distinction not only between patients with schizophrenia and bipolar disorder, but also 
between patients with schizoaffective disorder. This seems to be true independently of 
the phase of the disorder, with higher levels being characteristic of relapse and lower 
levels typical of remission.  
In our retrospective five−year study we confirmed that UCB mean levels are clearly 
higher in patients with acute psychotic episodes of the schizophrenia and 
schizoaffective spectrum, when compared with bipolar patients and healthy controls. 
Our results are similar to those already described before, although all patients of our 
sub−groups were in normal range for (unconjugated, conjugated and total) bilirubin 
values. Other important aspect of our results is that acute schizoaffective patients stand 
right in between the patients with schizophrenia and the patients with bipolar disorder. 
This data reinforces the theory that schizoaffective disorder, might be an intermediate 
clinical entity, so often misunderstood but somewhere in between the schizophrenic and 
the bipolar spectra, both in phenotypic and physiopathologic aspects. 
In our prospective twelve−month study, we verified that UCB mean levels were 
statistically significantly higher in relapsing psychotic patients with schizophrenia than 
in relapsing psychotic patients with schizoaffective disorder. We also confirmed that 
UCB mean levels were statistically significantly higher in remitting patients with 
schizophrenia than in remitting patients with schizoaffective disorder. This outcome 
gives us some insight on the possible role of UCB as a biomarker for categorical 
distinction between schizophrenia and schizoaffective disorder, not only during relapse 
but also during the partial remission of an acute psychotic state. 
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UCB serum level as a good biomarker candidate with psychopathological, 
psychosocial and dimensional potential for severity among groups of patients with 
the same psychotic disorder (schizophrenia and schizoaffective disorder) 
Our results also suggest that UCB serum levels may be a useful biomarker in the 
distinction not only between patients with schizophrenia and schizoaffective disorder, 
but also in the distinction between remission and relapse among both of these groups. 
In our prospective twelve−month study we confirmed that UCB mean levels are higher 
in patients with schizophrenia on relapse versus partial remission. We believe we failed 
to find a statistically significant difference for schizophrenia patients just because of our 
small sample size. Nevertheless we confirmed that UCB mean levels are statistically 
significantly higher in patients with schizoaffective disorder on relapse versus partial 
remission, and that is, to our knowledge the first time this kind of data is published. This 
outcome gives us some insight on the possible role of UCB as a biomarker for a 
dimensional distinction in schizoaffective disorder. We also found, through a linear 
regression model applied separately for patients with schizophrenia and patients with 
schizoaffective disorder, a statistically significant positive correlation between UCB 
mean levels at admission and Mean Length of Stay in patients with schizoaffective 
disorder suggesting that UCB may have a potential role as a biomarker for admission 
duration.  
We were also able to describe, for the first time, a positive correlation with significant 
statistically meaning, between UCB mean level of relapsing patients at the first 
assessment (admission) and the PSP item (d) “disturbing and aggressive behaviors”. 
Last but not least we have also found a new negative correlation, with significant 
statistically meaning, between the UCB mean level of remitting patients at the second 
assessment (outpatient appointment) and PANSS item G7 “psychomotor retardation”. 
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Symptomatology of schizophrenia is heterogeneous, there is not any pathognomonic 
symptom and the diagnosis is difficult, since it is based on subjective information, 
instead of markers (Garcia−Alvarez et al 2016). Given the heterogeneity of symptoms 
in patients with schizophrenia and current treatment limitations, biomarkers may play 
an important role in diagnosis, subtype stratification, and the assessment of treatment 
response (Goldsmith et al 2017).  
Identifying biomarkers that can be used as diagnostics or predictors of treatment 
response (theranostics) in people with schizophrenia will be an important step towards 
being able to provide personalized treatment (Lay et al 2016). Nevertheless 
understanding the biological process and progression of schizophrenia is the first step to 
developing novel approaches and interventions; therefore research on new biomarkers is 
extremely important when the goal is an early diagnosis and precise theranostics 
(Rodrigues−Amorim et al 2017). The combination of different markers, or complex 
multi−marker panels, might help in the discrimination of patients with different 
underlying pathologies and in the better classification of the more homogenous groups 
(Perkovic et al 2017).  
Schizophrenia is considered as a syndrome comprised by several disease phenotypes, 
covering a range of underlying pathologies, and one of these disease mechanisms seems 
to involve immune dysregulation and neuroinflammation (Kroken et al 2018). 
Schizophrenia is hypothesized to be a syndrome with different underlying pathological 
processes and the same is true for inflammation, which has various stages and 
processes, ranging from acute to chronic and can also be an autoimmune process 
(Müller 2018). An increasing number of clinical, epidemiological, and experimental 
studies have shown links between schizophrenia and inflammatory conditions 
(Feigenson et al 2014). The evidence to date, coupled with advances in immunology 
and genetics has afforded the field an unparalleled opportunity to investigate the 
hypothesis that a subset of patients with schizophrenia may manifest an 
immunophenotype, toward new potential diagnostics and therapeutics to reduce risk, 
alleviate symptoms, and improve quality of life in both at−risk populations and patients 
with established schizophrenia (Miller and Goldsmith 2017).   
Although there is no clear evidence to support widespread clinical use of inflammation 
as a biomarker in schizophrenia, future studies in this area show promise towards a 
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greater understanding of the etiopathophysiology of this heterogeneous syndrome, 
towards new potential diagnostics and therapeutics to reduce risk, alleviate symptoms 
and improve quality of life, in both at−risk and established patient populations (Miller 
and Goldsmith 2019).  
The vulnerability−stress−inflammation model may help to explain the role of 
inflammation in schizophrenia because stress can increase pro−inflammatory cytokines 
and may even contribute to a chronic pro−inflammatory state (Müller 2018). Chance 
findings often lead to later robust scientific discovery (Buckley 2019). A patient with 
treatment−refractory schizophrenia went into remission of his psychosis 
contemporaneously with the bone marrow treatment he received for leukemia (Miyaoka 
2017). His remission of psychosis was considered to be the result of immune cellular 
therapy; provocative indeed, but only time will tell whether immune dysfunction is a 
primary mechanism or a secondary consequence in the neurobiology of schizophrenia 
(Buckley 2019).  
All the already cited authors (Feigenson et al 2014, Lay et al 2016, Garcia−Alvarez et al 
2016, Miller and Goldsmith 2017, Goldsmith et al 2017, Perkovic et al 2017, 
Rodrigues−Amorim et al 2017, Kroken et al 2018, Müller 2018, Miller and Goldsmith 
2019, Buckley 2019) who wrote reviews regarding the importance of 
neuroinflammation in schizophrenia have not included UCB in their long lists of 
potential neuroinflammatory biomarkers. We hope that in the near future UCB will be 
brought to the attention of other groups of clinical researchers as we believe it is a lost 
piece on the fascinating neuroinflammatory jigsaw puzzle of schizophrenia.  
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General Limitations of our studies 
Unfortunately we had a high rate of patients lost to follow−up. On one hand we had 
some patients with psychosis secondary to drug abuse (e.g. cannabis) or organic 
conditions (e.g. temporal lobe epilepsy) that couldn’t meet criteria for schizophrenia nor 
schizoaffective disorder and had to be excluded from the study. On the other hand we 
had too many patients not coming to the second assessment, as it turned out to be very 
hard to convince psychotic patients (even in remission) to come to the psychiatric 
hospital, to see the physician just for research purposes.  
We are also aware of other problems that should be discussed. It would be important to 
have genetic tests to exclude GS;  cerebrospinal fluid analysis to exclude encephalitis;  a 
more specific electroencephalography analysis;  or even a more sensitive and specific 
brain scan with functional magnetic resonance imaging. We hope better studies in the 
future will address these issues. 
We would like to highlight that in neuropsychological evaluation (we were able to 
complete 120 neuropsychological assessments), we did not find any correlation with 
enough statistical significance between those results and the UCB levels. 
Last but not least, our study suggests a possible role of higher, yet normal, UCB mean 
levels as a risk factor for psychotic relapse, but we must recognize that we were not able 
to test or calculate neither specificity nor sensitivity of UCB as a biomarker for 
psychosis.  
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Research Perspectives for the future 
Unconjugated bilirubin seems to be a serious candidate for biomarker in the 
schizophrenia – schizoaffective – bipolar spectra. We believe that further similar studies 
with bigger samples will have more statistical power, yielding possibilities for 
replication of our results and help to clarify our findings.  
There is indeed some potential for other researchers to explore UCB as a biomarker for 
psychosis and further studies shall focus on the search for significant statistically 
correlations between UCB mean levels in psychotic patients and other kind of variables 
such as genetics, neuroimaging, neurophysiology and neuropsychology. These variables 
are quite important for the diagnosis and prognosis of the patients and this kind of work 
might become quite relevant for a better understanding of the etiology of psychotic 
disorders of the schizophrenia and schizoaffective spectrum. 
Another opportunity for possible research is the search for new therapeutic targets, as it 
is widely accepted that the classic treatment of schizophrenia and other psychotic 
disorder has changed very little in the last half of the century. New biological and 
disease−modifying therapies are urgently needed in order to increase the treatment 
chances of all patients that have been taking antipsychotics (a class of medication that is 
already on its third generation), many times, unfortunately, without achieving the 
desired full clinical remission, social recovery and/or gratifying quality of life. 
  




The results presented seem to support a role of UCB in the etiopathogeny of 
schizophrenia spectrum disorder and add novel information also regarding the 
schizoaffective disorder spectrum. According to these results UCB may have a possible 
role as a biomarker for categorical distinction between schizophrenia and 
schizoaffective disorder, especially during an acute psychotic state. Also they point to 
interesting dimensional correlations between the levels of this biomarker candidate and 
important clinical aspects, such as psychopathological (e.g. psychomotor retardation) 
and psychossocial (e.g. duration of psychiatric admission or disturbing and aggressive 
behaviors), thus yielding some predicting value potential. 
Despite the limitations already discussed we would like to propose a quite simple 
tridimensional model (Figure 7) that might be useful for studying the role of other 
biomarkers candidates in psychotic spectrum disorders. This model includes a 
categorical axis from affective to non−affective psychosis; a dimensional axis from 
personality to psychosis; and a biomarker axis from remission to relapse. 
Figure 7 – UCB as biomarker in the psychotic spectra tridimensional model.  
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LIST OF ABBREVIATIONS 
 
1H−MRS Proton Magnetic Resonance Spectroscopy 
ACC Anterior Cingulate Gyrus 
ALT Alanine Transaminase  
ANOVA Analysis of Variance 
APA American Psychiatry Association 
AST Aspartate Transaminase 
BD Bipolar Disorder 
BGL Blood Glucose Level 
BMI Body Mass Index 
BOMs Bilirubin Oxidative Metabolites 
BPRS Brief Psychiatric Rating Scale 
CB Conjugated Bilirubin  
CGI Clinical Global Impression 
Cho Choline  
CK Creatine Kinase 
CNS Central Nervous System 
Col Cholesterol 
CPR C Reactive Protein 
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CPZE Chlorpromazine Equivalent 
Cr Creatine 
CSF Cerebrospinal Fluid 
CT Computed Tomography 
dB Decibel 
DG Dentate Gyrus 
DSM IV Diagnostic and Statistical Manual of mental disorders, fourth edition 
DSM 5 Diagnostic and Statistical Manual of mental disorders, fifth edition 
DUP Duration of Untreated Psychosis 
EEG Electroencephalography 
FLAIR MR Fluid Attenuated Inversion Recovery Magnetic Resonance 
FPH Family Psychiatric History 
GA Gunn rat Aripiprazole group 
GAF Global Assessment of Functioning 
GC Gunn Control 
GGT Gamma−glutamyltransferase 
GH Gunn rat Haloperidol group 
GL Granular Layer 
GR Gunn rat Risperidone group 
GS Gilbert’s Syndrome 
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Iba1 Ionized Calcium Binding Adaptor Molecule 1 
ICD 9 International Classification of Diseases, ninth edition 
ICD 10 International Classification of Diseases, tenth edition 
ICD 11 International Classification of Diseases, eleventh edition 
IL1R Interleukin 1 Beta Receptor 
 IL1β Interleukin 1 Beta 
MFU Median Follow Up 
ML Molecular Layer 
ml Myoinositol 
MLS Mean Length of Stay 
ms Milliseconds 
NAA N Acetylaspartate  
NMDA N Methyl D Aspartate 
NO Nitric Oxide 
OLGs Oligodendrocytes 
PANSS Positive And Negative Syndrome Scale 
PhD Philosophy Doctor 
PPI Prepulse Inhibition 
PRISMA Preferred Reporting Items for Systematic reviews and Meta−Analyses 
PSP Personal and Social Performance 
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ROS Reactive Oxygen Species  
SD Standard Deviation 
SGZ Subgranular Zone 
SPSS Statistical Package for the Social Sciences 
SPY Smoking Pack Years 
SZ Schizophrenia 
TAG Triacylglyceride 
TB Total Bilirubin  
TNFR1 Tumor Necrosis Factor Alfa Receptor 1 
TNFα Tumor Necrosis Factor Alfa 
UCB Unconjugated Bilirubin 
UGT1A1 Uridinediphosphate Glucuronosyltransferase 1A1 
VHB Viral Hepatitis type B 
VHC Viral Hepatitis type C 
WC Wistar rat Control group 
WHO World Health Organization 
WM Wistar rat Medication group 
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